1	Estimation of Lassa fever incidence rates in West Africa: development of a modeling framework to
2	inform vaccine trial design
3	
4	Sean M. Moore ^{1,^,#} , Erica Rapheal ² , Sandra Mendoza Guerrero ^{3,*} , Natalie E. Dean ⁴ , Steven T. Stoddard ^{3,*}
5	
6	¹ Department of Biological Sciences, University of Notre Dame, Notre Dame, IN USA
7	² Independent Consultant
8	³ Emergent Biosolutions, Inc., Gaithersburg, MD USA
9	⁴ Department of Biostatistics & Bioinformatics, Emory Rollins School of Public Health, Atlanta, GA USA
10 11	[^] Current address: Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD USA
12	* Current address: Bavarian Nordic, Inc., San Diego, CA USA
13	[#] Correspondence: <u>smoore15@nd.edu</u>
14	

15 Short Title: Modeling Lassa fever to inform vaccine trial design

16 Abstract

17 Background

- 18 Lassa fever (LF) is an acute viral hemorrhagic disease endemic to West Africa that has been declared a
- 19 priority disease by the World Health Organization due to its severity and the lack of a vaccine or
- 20 effective treatment options. Several candidate vaccines are currently in development and are expected
- to be ready for phase III field efficacy trials soon. However, most LF cases and deaths are believed to go
- 22 unreported, and as a result we lack a clear understanding of several aspects of LF epidemiology and
- immunology that are critical to the design of vaccine efficacy trials.
- 24 Methods
- To help guide vaccine trial design and site selection we estimated the force of infection (FOI) in all 1st
- 26 and 2nd administrative units in West Africa from published seroprevalence studies. We next estimated LF
- 27 reporting probabilities using these FOI estimates and LF case and death reports and then projected FOI
- in all admin1 and admin2 areas without seroprevalence data. We then extrapolated age-specific LF
- 29 incidence rates from FOI estimates under different assumptions regarding the level of protection against
- 30 reinfection among seropositive and seronegative individuals with a history of prior infection.

31 Results

32 Projected FOI estimates and modeled annual LF incidence rates indicate that Sierra Leone, southern

33 Guinea, and a few areas within Nigeria would likely yield the highest LF case incidence rates during a

34 vaccine trial. Estimated LF incidence rates were highly sensitive to assumptions about Lassa

immunology, particularly the frequency of seroreversion among previously infected individuals and the

36 extent to which seroreverted individuals retain protection against reinfection and more severe disease

37 outcomes.

38 Conclusions

Our spatial LF incidence rate estimates, along with the interannual and seasonal variability in these 39 40 estimates and estimates of baseline seroprevalence, could be used for vaccine trial site selection, 41 choosing the target population (e.g., age and serostatus), and maximizing a trial's statistical power. 42 **Author Summary** 43 Lassa fever virus infects an estimated 100,000-300,000 people and kills 5,000 people annually in West 44 Africa. Incidence rates appear to be highly spatially heterogeneous within the endemic region; however, 45 the true nature is uncertain due to significant surveillance gaps. We modeled Lassa Fever disease 46 incidence at a sub-national scale throughout West Africa to inform the design of vaccine efficacy trials. 47 We find considerable spatial heterogeneity in incidence rates, with the highest rates concentrated in 48 Sierra Leone, Guinea, and a few areas of Nigeria. Even though we estimate that <1% of infections are 49 reported, our estimates also indicate that using symptomatic LF as a primary endpoint will require tens 50 of thousands of trial participants to demonstrate vaccine efficacy. Our work highlights data gaps and 51 uncertainties related to the ecology and epidemiology of LASV that limit our ability to estimate and 52 predict disease incidence. 53

54 Introduction

Lassa fever (LF) is an acute viral hemorrhagic illness endemic to West Africa. LF is caused by infection with Lassa virus (LASV), an arenavirus that circulates in rodent populations but can spill over to human populations.¹ Transmission is thought to occur through human contact with rodents either due to infestation of human residences or processing for food.² Importantly, direct human-to-human transmission in nosocomial settings also occurs, creating a potential for wider spread of the virus to naive populations.² Most LASV infections are presumed to be asymptomatic or result in mild disease, but up to 20% can result in a severe, life-threatening hemorrhagic illness.² In these instances, case

fatality rates among clinical LF cases can reach 60%.¹ Previous studies have estimated that 100,000-62 63 300,000 LASV infections and 5,000 LF deaths occur annually in sub-Saharan Africa. However, these estimates were extrapolated from limited serological studies conducted decades ago and may not 64 accurately reflect current conditions across West Africa.^{3,4} 65 66 Despite its severity and burden, there are currently few therapeutic options for LF and no licensed 67 vaccines.¹ In 2018, the World Health Organization (WHO) declared LF a 'Priority Disease,' and the 68 Coalition for Epidemic Preparedness Innovations (CEPI) subsequently invested in the development of six LF vaccine candidates, four of which have entered clinical trials.¹¹ Individuals previously infected with 69 70 LASV maintain LASV-specific CD4+ memory T cells for years after the infection has cleared.⁶ This, along 71 with animal vaccination models, suggests that vaccination will provide meaningful protective immunity against severe LF.¹² However, there are currently no immunological correlates of protection against LF 72 73 and the risk of severe disease rules out the option of controlled human infection studies to evaluate the clinical benefit of a candidate vaccine.¹³ Instead, field efficacy trials are necessary to determine the 74 75 efficacy of vaccine candidates.

Assuming a primary endpoint of PCR-positive symptomatic LF disease, CEPI has targeted a minimum 76 77 annual LF incidence rate of 1% to ensure an adequately powered trial. An ideal study site will have a baseline seroprevalence that indicates the presence of frequent LASV spillover, but which is low enough 78 79 that existing immunity in the population does not substantially reduce the LF incidence rate. Identifying 80 populations in which these criteria are likely to be met is the most critical consideration in Lassa vaccine trial design.^{7,8} However, our understanding of Lassa epidemiology is limited by a lack of good prospective 81 82 epidemiological data and inconsistent disease surveillance across West Africa. Since 2018, reported LF 83 case counts have increased dramatically, although this is partly due to changes in surveillance and diagnostics.⁵ Other than a couple of prospective community studies in Sierra Leone and Mali that tested 84 85 individuals for evidence of a recent LASV infection,^{3,7} and a few hospital-based surveillance studies of

86	severe LF cases, ^{8,9} most epidemiological data on Lassa come from national surveillance programs. A
87	majority of LF cases are not detected by current clinical surveillance systems because common LF
88	symptoms—such as fever, malaise, headache, and muscle pain—closely resemble those of other febrile
89	illnesses endemic to the region. ^{1,2,11} In addition, the extent of national LF surveillance varies considerably
90	from country to country in West Africa, complicating comparisons of incidence rates between different
91	LF-endemic areas. For example, Nigeria has expanded LF surveillance over the past decade, ^{5,12} while
92	changes in healthcare-seeking behaviors in areas of Sierra Leone heavily impacted by the 2013-2016
93	Ebola virus epidemic have led to declines in the detection of febrile illnesses, including LF. ^{9,13}
94	Because of the limited availability of epidemiological data for Lassa, in 2020 CEPI initiated a long-term,
95	multi-country, prospective epidemiological study of Lassa disease and infection in West Africa. ¹⁴ This
96	study, called Enable, is tracking over 20,000 participants across five West African countries with the goal
97	of identifying baseline seroprevalence, LASV infection rates, LF incidence rates, serological dynamics,
98	and individual and community-level risk factors for infection and disease. Due to the impact of the
99	COVID-19 pandemic, data from the Enable study have not yet been published. However, preliminary
100	findings from the study presented in an interim report suggest that LASV infection is common in several
101	of the study locations and that prior infection does not confer lifelong immunity. ¹⁵ Epidemiological data
102	such as those being collected in Enable are essential for understanding the current status of Lassa in the
103	region. In the absence of detailed epidemiological data across the entire geographic range of LF,
104	statistical models can be used to anticipate the future disease incidence for the purpose of vaccine trial
105	planning. Such a modeling framework, based on existing epidemiological data and accounting for the
106	factors that drive pathogen transmission and infection risk, can incorporate new epidemiological data
107	from Enable and other studies as it becomes available. This framework can include ecological factors
108	that influence the spatial and temporal patterns of disease and immunological factors related to
109	immunity.

LASV is thought to infect humans through exposure to the urine or feces of the multimammate rat, 110 *Mastomys natalensis,* which serves as the primary reservoir host.¹⁶ As a result, LASV spillover typically 111 112 occurs seasonally in rural and peri-urban areas of West Africa where agricultural practices, socioeconomic factors, and the built environment promote rodent-human interactions.^{17–19} Field studies 113 114 have identified several risk factors associated with M. natalensis abundance in villages and individual 115 houses, but have also found that M. natalensis abundance and LASV seropositivity in rodents are spatially heterogeneous at multiple spatial scales, from the village- to the subnational-level.^{20–22} 116 117 Moreover, incidence of disease can be markedly seasonal on broad spatial scales, suggesting important 118 variation in either rodent infection rates or contact with humans. Overall, the substantial spatial and 119 temporal variation in LASV prevalence is an important consideration for vaccine trial site selection, as 120 potential trial locations might have different LF incidence rates despite their proximity and similar 121 environmental conditions. 122 Because of the scarcity of longitudinal data, it is difficult to assess LF incidence, the duration of immunity 123 following infection, or reinfection rates. Two longitudinal serology studies have found evidence that 3-124 6% of seropositive individuals seroreverted from IgG+ to IgG- between sampling periods, suggesting that infection-induced immunity may not be permanent.^{23,24} Preliminary data from CEPI's Enable study also 125 indicate that seroreversion occurs relatively frequently.¹⁴ A further complication for our understanding 126 127 of LASV infection rates is that the frequency of severe LF following infection is uncertain. It is typically 128 stated that 80% of Lassa fever infections are asymptomatic, but data supporting this assumption is 129 extremely limited.²

Reliable estimates of sub-national LF incidence rates and baseline population-level immunity are needed
to inform trial site selection and enable successful LF vaccine efficacy trials. In lieu of detailed
geographical measurements, these epidemiological indicators can be modeled from available incidence
and seroprevalence data. Here, we use an epidemiological model to estimate LASV spillover rates and

the annual number of community-level LF cases at the 1st and 2nd administrative levels across West
Africa. We provide sub-national estimates of baseline seroprevalence and expected age-specific LF
incidence rates to help guide trial selection. We also explore the sensitivity of our estimates to different
assumptions of LF immunology, including the proportion of infections that are symptomatic, the level of
protection provided by prior infection, and the duration of this protection.

139 Methods

140 *Model development*

141 We integrated publicly available epidemiological data into a unified modeling framework for LF in West 142 Africa. We applied this model to investigate key questions regarding vaccine trial design including the 143 expected incidence rates for trial endpoints of disease and infection, the target population (e.g., geographical location, age range, and serostatus of participants), and sample size considerations 144 145 (number of sites, number of enrollees). The model was adapted from an existing model originally 146 designed to predict spillover of LASV and model reactive vaccination strategies during an LF outbreak.⁶¹ 147 To better understand the magnitude and spatiotemporal distribution of LASV spillover rates and LF 148 incidence in endemic areas, we refined the model to focus on estimating the annual force of infection 149 (FOI), the rate at which susceptible individuals in a population are infected. The updated model also 150 incorporates the potential for seroreversion (seropositive individuals becoming seronegative over time 151 due to antibody waning). FOI estimates at the 1st and 2nd administrative levels were used to estimate 152 seasonal and interannual LF incidence rates across the study region. Rates were investigated in different 153 potential target populations defined by serostatus and age.

154 a. Epidemiological data

In our epidemiological model, we included 14 West African countries (Senegal, Gambia, Guinea-Bissau,
Guinea, Sierra Leone, Liberia, Côte D'Ivoire, Ghana, Benin, Togo, Nigeria, Niger, Burkina Faso, and Mali),

plus the administrative districts in Cameroon bordering Nigeria, which encompasses the known range of 157 158 LASV (Figure 1). Given the extensive spatial heterogeneity in LF incidence, we collated epidemiological data at the 1st and 2nd administrative levels (admin1 and admin2) in each country within the study 159 160 region. For example, in Nigeria admin1 is the state level and admin2 is the local government area (LGA) 161 level; in Sierra Leone admin1 corresponds to the province level and admin2 is the district level. The 162 epidemiological data included in the study comprised two types: (a) age-stratified serology data to 163 detect evidence of past infection and (b) reports of suspected and confirmed LF cases and deaths in 164 humans. Epidemiological data was initially collated through the end of 2020 from multiple sources 165 (including WHO outbreak reports, ProMED reports, country-level reports, and a literature search) and used in a previous analysis (see Table S1 in Lerch et al. 2022).⁶¹ For the current analysis we searched the 166 167 same sources for additional datasets through early 2023. We excluded seroprevalence studies from 168 before 1980 or where the location of the study population could not be identified at a sub-national 169 level. We also excluded seroprevalence studies that focused only a specific target population (generally 170 healthcare workers) that may not be representative of the overall population in the study area due to 171 unequal exposure to spillover or human-to-human transmission. All included studies were aggregated to 172 the admin1 and admin2 levels.

173 Where possible, case data was categorized into cases of documented or suspected human-to-human 174 transmission, documented or suspected spillover cases, and cases of unknown origin. Cases of 175 documented or suspected human-to-human transmission were excluded from the estimation of 176 spillover rates. Only cases and deaths from 2010-2023 were included in our analysis, because the 177 case/death data were used to estimate the fraction of LF cases that are reported and LF surveillance 178 systems have changed substantially in the past decade.^{5,62} Yearly, age-specific country-level population 179 data from 1960-2015 were obtained from UN World Population Prospects estimates and downscaled to the admin1 and admin2 levels using population raster data from Worldpop.^{64, 63} 180





Figure 1. Study region covering the hypothesized zone of Lassa fever (LF) endemicity. Areas in orange
 are (A) 1st administrative level units and (B) 2nd administrative level units that have reported LF cases or
 deaths from 2010-2023. In some locations, data were only reported at the 1st administrative level.

186 b. Covariate data

187 To identify population-level covariates associated with LF occurrence, we used spatial datasets of

188 environmental, climate, and socioeconomic variables that have been hypothesized to be associated with

- 189 LF occurrence or transmission.^{8,31,40,42,43,51,53,64,65} These variables included monthly precipitation, monthly
- 190 average temperature, monthly normalized difference vegetation index (NDVI), elevation, latitude,
- 191 longitude, travel time to the nearest urban center,⁶⁶ the Healthcare Access and Quality Index (HAQ)

based on mortality from causes amenable to personal health care,⁶⁷ proportion of land cover that was a 192 tropical ecotype⁶⁸, proportion of agricultural land,⁶⁹ average forest loss over the past 20 years,⁷⁰ an 193 improved housing measure,⁷¹ a poverty index (percentage of households with an International Wealth 194 Index value below 35),⁷² the occurrence of hunting for bushmeat,⁷³ the probability of *Mastomys* 195 occurrence,²⁵ and the probability of LASV occurrence in *Mastomys* (Table S2).²⁵ Each covariate was 196 197 averaged to the admin1 and admin2 level. Within the study region, the improved housing measure or Mastomys occurrence data was missing for some administrative units in northern Senegal, Mali, and 198 199 Niger, where there is no evidence of LF occurrence, so these administrative units were excluded from 200 our analysis. To reduce the number of variables in our regression models we performed principal 201 component analyses for monthly precipitation, monthly temperature, and monthly NDVI using the 202 'prcomp' function in R. The first two principal components (PCs) for NDVI explained >90% of the 203 variation in monthly NDVI, and the first three PCs for precipitation and temperature each 204 explained >90% of the variation for these two variables, so these PCs were used in place of the monthly 205 values in subsequent analyses.

206 c. Model

207 A multistep process was used to model LF attack rates from recent epidemiological data: (1) estimation 208 of the recent force of infection (FOI) in administrative units with available seroprevalence data, (2) 209 estimation of the proportion of LF cases and deaths that were detected and reported in administrative 210 units using both seroprevalence data and case/death data, (3) estimation of the annual LASV spillover 211 infection rate in all administrative units with case/death data based on the underreporting estimates 212 from the previous step, (4) projection of the annual FOI for these administrative units based on these 213 spillover rates, (5) calculation of the population-level infection history in each administrative unit based 214 on these FOI estimates, (6) calculation of age-specific infection attack rates and LF incidence rates in 215 each administrative unit under several different scenarios regarding the rates of seroreversion and the

- susceptibility to infection and disease among seropositive and seroreverted individuals (Table 1, Figure
- 217 2). This modeling process was conducted at both the 1st and 2nd administrative levels. In addition, we
- 218 used statistical and machine learning methods to estimate annual FOI in each administrative unit based
- on the covariates in Table S2 and compared these estimates to the model projections from step 4. This
- 220 analysis was conducted to determine whether environmental variables associated with LF occurrence
- 221 could be used to estimate LASV spillover in the absence of human serology or case data. A brief
- description of each step in this process is provided below, with additional details of the complete
- 223 process provided in the supplementary materials (S1 Appendix).



225	Figure 2. Modeling framework schematic. Our modeling framework involved seven sequential steps
226	that result in a set of ensemble models of the FOI and annual incidence of LF in each of the 1^{st} and 2^{nd}
227	administrative levels across West Africa. FOI estimates were projected and estimated for three different
228	seroreversion rates, and LF incidence rates were estimated for 18 scenarios: 3 different seroreversion
229	rates, 3 different assumptions about the susceptibility of seropositive individuals to disease, and 2
230	different assumptions about the susceptibility of seroreverted individuals to disease.
231	
232	1. Estimating the Force of Infection from Serology Data
233	Estimates of the annual FOI were obtained for each 1 st or 2 nd level administrative unit where serological
234	data were available from 1980 - 2023 using a catalytic model and assuming a constant FOI (λ) over time.
235	We estimated FOI assuming either a 0%, 3% (observed in Mali by Safronetz et al. 2017), ⁷ or 6%
236	seroreversion rate (observed in Sierra Leone by McCormick et al. 1987). ²³ In the absence of
237	seroreversion, and assuming all infected individuals develop detectable antibody levels following
238	infection, the proportion of a population that will be seropositive at age a is determined by the FOI (λ):
239	$p(a) = 1 - e^{-\lambda a}.$ (1)
240	If antibodies wane over time and some individuals serorevert from IgG+ to IgG-, then the proportion of

the population seropositive at age a can be estimated using a reverse catalytic model:

242
$$p(a) = \frac{\lambda}{\lambda + \pi} \left(1 - e^{-(\lambda + \pi)a} \right), \tag{2}$$

243 where π is the annual seroreversion rate. Equation (2) simplifies to equation (1) when $\pi = 0$. 244 Serology data for FOI estimation was obtained for 24 1st-level administrative units and 53 2nd-level 245 administrative units. Additional details regarding how FOI was estimated from serology data are 246 provided in S1 Appendix.

247 **2.** Estimating Country-specific Reporting Fractions

248 For each administrative unit where the FOI was estimated from serology data in the previous step, we 249 estimated the fraction of infections that went unreported from 2010-2023 based on the discrepancy 250 between reported LF cases and deaths and the annual number of infections predicted by the FOI 251 estimates from those sites under the three different seroreversion scenarios. We first estimated the 252 location-specific fraction of infections that went underreported, the fraction that resulted in a reported 253 LF case, and the fraction that resulted in a reported LF death using a method adapted from Perkins et al. 254 (2021).⁷⁴ The estimation process was repeated using 1000 draws from the posterior FOI estimates from 255 step 1 to generate posterior distributions for the reporting fractions. Country-specific reporting fractions 256 were then estimated from all available admin1 or admin2 level estimates within each country and used to extrapolate infections from LF case and death data in locations without serology data in step 3. 257 258 **3.** Estimating LASV spillover rates 259 For each administrative unit, we next estimated the total number of annual infections, I_{ij} based on the

reported LF cases and deaths from 2010-2023 along with the estimated reporting fractions from theprevious step using maximum likelihood estimation.

262 **4.** Projecting the FOI from estimated LASV spillover rates

For each administrative unit where LASV spillover infections were estimated from LF case/death data in step 3, we then projected the underlying FOI that would correspond to the estimated infection rate. The projected FOI_i for each administrative unit *i* was obtained by minimizing the difference between the number of infections, I_i, estimated in the previous step and the expected number of infections arising from a given FOI in the reverse catalytic model from equation (2) using the *optim* function in R. This resulted in a posterior distribution of FOI_i for each admin1 and admin2 unit.

269 **5.** Estimation of Population-level Infection Histories

The FOI projections generated from serology and case data in step 4 were then used to simulate population-level infection histories for each admin1 and admin2 unit. For the FOI projections, we drew 1,000 samples for each administrative unit from the posterior distribution and computed the proportion of the population that had been infected by age *a* using the catalytic model in equation (1), and the proportion of the population seropositive at age *a* using the reverse catalytic model in equation (2) for the three different seroreversion rates.

276 **6.** Estimating LASV Infection and LF Attack Rates

277 The inferred population-level infection histories and FOI estimates were then used to compute the 278 expected number of infections in each admin1 or admin2 administrative unit. We examined several 279 different scenarios regarding the risk of seropositive or seroreverted individuals becoming reinfected 280 and developing LF (Table 1). Reinfection of seropositive individuals, as defined by a fourfold increase in 281 antibody titers, was observed in Sierra Leone by McCormick et al. (1987) and in the preliminary results from the ongoing Enable study.^{27,14} In addition, the Enable study reported LF cases among individuals 282 283 who were seropositive at baseline, indicating that prior infection does not entirely protect an individual 284 from developing disease if they are reinfected (unpublished data).¹⁴ Therefore, we considered three 285 scenarios for the susceptibility of seropositive individuals to symptomatic infection: (a) no risk, (b) a 286 reduced risk informed by the rates of infection observed in seronegative vs. seropositive individuals 287 observed by McCormick et al. (1987) and Enable (relative risk (RR) = 0.53), or (c) a reduced risk informed 288 by the relative rates of LF cases observed in individuals who were seropositive vs. seronegative at 289 baseline in the Enable study (RR=0.36).

Table 1. Immunological parameters included in model sensitivity analysis, and the low, medium, and
high values considered for each parameter. Lassa fever relative risk values are in comparison to fully
susceptible individuals with no history of LASV infection.

Parameter	Low	Medium	High
Seroreversion rate	0% / yr	3% / yr	6% / yr
Lassa fever relative risk	0	0.36	0.53
(seropositive individuals)			
Lassa fever relative risk	0.53	-	1
(seroreverted individuals)			

293

294 Although simple reverse catalytic models generally assume that seroreverted individuals are susceptible 295 to reinfection, an individual may still have protection against developing moderate or severe disease 296 even if their antibody titers have dropped below the detectable limit. At present this possibility has not 297 been addressed for LASV, so we considered two scenarios: (a) seroreverted individuals are completely 298 susceptible to reinfection and illness, and (b) seroreverted individuals can be reinfected but have a 299 reduced probability of developing LF based on the reduced rate of reinfection experienced by 300 seronegative vs. seropositive individuals (RR=0.53). 301 Including our three seroreversion rate scenarios, we therefore consider a total of 18 (3x3x2) scenarios 302 regarding the role of immunity in modulating susceptibility and influencing LF attack rates. The expected 303 annual number of infections in administrative unit *i* were calculated from the FOI_i using the reverse 304 catalytic model in equation (2) for each of the 18 different scenarios at both the admin1 and admin2 305 levels. The number of infections was multiplied by the symptomatic probability (20%) to obtain an 306 estimate of the expected annual number of LF cases in each administrative unit. 307 To account for the observed seasonality in human LF cases, we fit a beta distribution to the timing of 308 reported LF cases in Nigeria, Liberia, and Sierra Leone, and simulated the timing of LF cases as a random

draw from that distribution. For countries where we could not estimate seasonality, we assumed an

- 310 average of the observed seasonality in Nigeria, Liberia, and Sierra Leone.
- 311 Modeling the FOI from covariate data

312 There is a large degree of uncertainty in the estimated spillover rates for administrative units that have

313 reported only a small number of LF cases due to the large proportion of asymptomatic infections and

314 low reporting probabilities. Therefore, we used several statistical models to explore the relationships

between our FOI estimates from step 4 and several key spatial covariates (Table S2). These statistical

regression models were fit to the projected FOI_i estimates from administrative units with either serology

data or reported LF case/death data (N=77 of 164 admin1s, N=372 of 1,375 admin2s). The fitted models

318 were then used to predict FOI in the administrative units with no serology or case data.

319 Given that we have limited historical data and high uncertainty in our projected FOI estimates, we

320 considered eight different statistical models, as well as a null model with a single FOI estimated across

321 all administrative units. For each seroreversion scenario, we generated an ensemble model projection of

322 FOI in each admin1 or admin2 from the eight statistical models. Ensemble weights for each of the eight

323 models were calculated based on the performance of the individual model at predicting data withheld

324 from the model fitting step using a ten-fold cross-validation technique. Further details on the individual

325 statistical models and the ensemble approach are presented in S1 Appendix.

326 Results

327 Literature review

328 Thirty-one papers were selected for in-depth literature review. Topics of interest were Lassa serology (n

329 = 12), rodent epidemiology (n = 10), environmental risk factors and seasonality (n = 5), and LF

330 incidence/symptomatic rates (n = 4). Studies took place in Sierra Leone (n = 7), Guinea (n = 7), Nigeria (n

= 10), Ghana (n = 1), and Mali (n = 3). Three studies included all LF cases in Africa or globally (including

332 imported cases). Most studies were published in the last 10 years (n = 21). Seven studies were published 333 between 2000 and 2013, and three studies were from before 2000. LASV IgG seroprevalence varied 334 from 4% to 60%; in general, rates were higher in forest and savannah regions and lower near the coast and in the highlands.^{40–43} Seroprevalence in rodents is similarly variable, with IgG positivity between 6-335 336 52%,^{29,53–56} and PCR positivity between 1- 87%.^{58,59} One study in Guinea found that individual villages 337 showed some interannual variation in rodent seropositivity, but that all villages studied maintained at least 20% positivity from year to year.⁵⁷ Studies of seroreversion rates in Sierra Leone and Mali found 6 338 and 3% of seropositive individuals, respectively, reverted to seronegative in a given year.^{23,29} It is 339 340 typically assumed that 80% of Lassa fever infections are asymptomatic, but data supporting this 341 assumption is extremely limited. All studies included are shown in Table S1. 342 FOI estimates from serology The FOI was estimated from serology data available from 1980-2023 for 24 1st-level administrative units 343 and 53 2nd-level administrative units. FOI was estimated for at least one administrative unit in Côte 344 345 d'Ivoire, Ghana, Guinea, Liberia, Mali, Nigeria, and Sierra Leone (Figure 3). Under the assumption of no 346 seroreversion, the highest FOI at the admin1 level was in Ondo State, Nigeria (0.036/yr; 95% Credible 347 Interval (CrI): 0.027-0.047) and the highest FOI at the admin2 level was in Moyamba District, Sierra 348 Leone (0.063/yr; 95% CrI: 0.042-0.090) followed by Ose LGA in Ondo State, Nigeria (0.052/yr; 95% CrI: 349 0.037-0.071). The FOI estimates assuming annual seroreversion rates of 3% or 6% were higher than FOI 350 estimates without seroreversion. Ondo State, Nigeria remained the highest FOI at the admin1 level, with 351 the estimate increasing to 0.065 (95% CrI: 0.047-0.086) with a 3% seroreversion rate and 0.099/yr (95% 352 CrI: 0.071-0.133) with a 6% seroreversion rate. At the admin2 level Ose LGA, Nigeria had the highest FOI 353 estimate with 3% or 6% seroreversion rates, followed by Moyamba District, Sierra Leone and Esan West 354 LGA in Edo State, Nigeria.

355





359 Estimates of underreporting

360 Estimates of the probability that a LASV infection would be reported as an LF case were estimated for

- 361 each of the countries with serology and LF case data (Côte d'Ivoire, Ghana, Guinea, Liberia, Mali, Nigeria,
- 362 and Sierra Leone). In addition, we estimated the average reporting probability across the study region,
- 363 which was used to estimate LASV infections and FOI in countries that did not have serology data. Due to

364	the higher FOI estimates with seroreversion, the probability of a LASV infection being reported was
365	highest when we assumed no seroreversion and lowest with a seroreversion rate of 6%. Assuming a 6%
366	seroreversion rate, the average probability that a LASV infection would be reported as a LF case or death
367	at the admin1 level was 0.18%. The country-specific reporting probability ranged from a low of 0.20% in
368	Ghana and Guinea, to a high of 1.08% in Nigeria. At the admin2 level, the average probability that a
369	LASV infection would be reported as a LF case or death was 2.1%. This higher reporting probability was
370	largely driven by the results of one serology study that found low seroprevalence in two LGAs in Edo
371	State, Nigeria that are considered transmission hotspots. ⁷⁵
372	FOI projections from LF case data and reporting probabilities
373	The projected FOI estimates from LF case data and estimated country-specific reporting probabilities
374	varied considerably across the study region, with evidence of spatial heterogeneity within and between
375	countries (Figure 4, Figures S1-S2). In particular, there was substantial heterogeneity in FOI estimates at
376	the admin1 and admin2 levels within Nigeria. Because serology data were only available for 3 out of 774
377	LGAs within Nigeria (admin2), these FOI estimates are primarily informed by the LF case and death data,
378	which also shows significant spatial variability (e.g., see Redding et al. 2021). ⁶⁴ The magnitude of FOI
379	estimates, but not their spatial distribution, varied with the seroreversion rate.



381

382



385

386 Estimates of FOI from individual statistical and ensemble models

Among the statistical and machine learning models we explored to characterize the explanatory value of the covariates in Table S2, the random forest model provided the best fit to the projected FOI estimates at the admin1 level (r^2 =0.95), followed by the boosted regression model (r^2 =0.78; Figure 5, Figure S3). At the admin2 level, the random forest model again provided the best fit (r^2 =0.96), followed by the linear

391 model with interactions (r^2 =0.83; Figure S4). The Gaussian Markov random field (GMRF) models with 392 covariates also fit the projected FOI estimates better than GMRF models without covariates (Figures S3-S4) suggesting that the covariates provide some useful information. At the admin1 level, the most 393 394 important covariates in the random forest model were longitude, travel time to the nearest urban 395 center, and the Healthcare access and quality index (HAQ) (see Table S3 for full list of covariate 396 importance). center, and the estimated probability of LASV presence in Mastomys natalensis (Table S4). 397 At the admin2 level, the most important covariates in the random forest model were longitude, HAQ, 398 and the 2nd precipitation PC (Table S5). The performance of the model predictions on data held out of the regression for model validation was much lower for the 1st administrative level, with random forest 399 400 providing the best fit to the testing data ($r^2=0.32$), suggesting that the models are overfitting to the 401 training dataset (Figure S5). The cross-validation performance of most regression models was better at the 2nd administrative unit, with the random forest model providing the best fit (r²=0.76), and the 402 403 boosted regression and GMRF models with and without covariates all maintaining an r²>0.70 (Figure S6). 404 The low ratio of data points per covariate at the admin1 level may explain the poor cross-validation 405 performance relative to the admin2 level (N=77 for admin1 vs. N=372 for admin2). 406 Our ensemble model consisted of a weighted combination of the FOI predictions of each individual statistical regression model, along with a noise term. The ensemble model FOI estimates at the 2nd 407 408 administrative unit (Figures S7-S9) show much less spatial heterogeneity than the projected FOI 409 estimates from LF case data and reporting probabilities (Figure 4B). This largely results from the higher 410 weighting of the GMRF models, which include spatial smoothing (45.7% combined among the four 411 GMRF models). This spatial smoothing results in lower FOI estimates in the few projected Nigerian 412 hotspots, and lower within- and among-country variation in FOI estimates overall. Further details on the 413 results of the statistical and ensemble modeling are presented in the supplement (SI Results).

414





Figure 5. Scatterplots showing the relationship between the statistical regression predictions of FOI on the x-axis versus the FOI estimates projected from LF case data and reporting probabilities for the best performing statistical models included in our analysis. (A) Results of random forest model, and (B) results of boosted regression tree model. Plots are restricted to FOI estimates that were used in model fitting and do not include data held out for model validation. Results are for the 1st administrative level and a 6% seroreversion rate. Grey lines around points represent error bars for both direct and regression estimates of FOI values.

424

425 LASV infection attack rates and LF incidence rates

426 Due to the positive association between the assumed seroreversion rate and FOI, the highest LASV

427 infection attack rates and LF case incidence rates occurred in scenarios with a seroreversion rate of 6%.

- 428 For a given seroreversion rate, LF case incidence rates were lowest when seropositive individuals were
- 429 assumed to be protected from infection, intermediate when they had a relative risk of 0.36 for

developing LF compared to seronegative individuals, and highest when they had a relative risk of 0.53
for reinfection and disease. When seroreverted individuals were assumed to have partial protection
against LF, incidence rates were lower than when seroreverted individuals were assumed to be fully
susceptible. Therefore, estimated LF incidence rates were highest when we assumed that seroreversion
was frequent (6%), and that both seroreverted and seropositive individuals remained susceptible to
infection and disease.

436 Due to the spatial heterogeneity in our FOI estimates, the highest LF incidence rates were found at the

437 admin2 as opposed to the admin1 level. No admin1 units had an LF incidence rate of greater than 10 per

438 1,000 (1%) with a 0% or 3% seroreversion rate, and only Ondo State in Nigeria had an LG incidence

rate >10/1,000 at a 6% seroreversion rate based on our projected FOI estimates (Table 2 and Tables

440 S7,S9). In general, there was a wider range of annual LF incidence rates with the projected FOI

estimates than the ensemble model FOI estimates, due to the smoothing effects of the ensemble model.

442 For example, no Nigerian states were in the top-20 using the ensemble model estimates despite Ondo,

Ebonyi, and Edo States all being in the top-20 based on the projected FOI estimates. Due to the over-

smoothing effect observed in the ensemble model, we focus on LF incidence rates derived from the

445 projected FOI estimates in the rest of our results.

446 At the 2nd administrative level, LF incidence rates calculated from projected FOI estimates were >10 per 447 1,000 for several administrative units with seroreversion rates of 3% or 6%, but not 0% (Table 3 and 448 Tables S8,S10). While the influence of different assumptions regarding the susceptibility of seropositive 449 and seroreverted individuals to LF was minor at lower incidence rates, their impact is more apparent for 450 the admin2 units with the highest incidence rates (Table 3). For example, for Ose LGA, Nigeria, the 451 admin2 with the highest FOI, the median annual LF incidence rate increased from 9.7 per 1,000 when 452 seropositive individuals had full immunity and seroreverted individuals had partial protection, to 12.4 453 per 1,000 when seropositive individuals were fully immune but seroreverted individuals had no

- 454 protection, to 24.7 per 1,000 when seropositive individuals were only partially immune and
- 455 seroreverted individuals had no protection. Four admin2 units (two in Sierra Leone, one in Nigeria, and
- 456 one in Guinea) had LF incidence rates <10 per 1,000 when seropositive individuals were fully protected,
- 457 but incidence rates above 10 per 1,000 when we assume seropositive individuals were susceptible to
- 458 reinfection and illness.

459 Table 2. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 1st administrative level when the seroreversion rate is

- 460 **6%.** LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in
- 461 seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

		Annual Lassa Fever incidence rate (per 1,000)							
		Ser	oreverted – No Immu	inity	Seror	everted – Partial Im	munity		
		Seropos. – Full	Seropos. – Part.	Seropos. – Part.	Seropos. – Full	Seropos. – Part.	Seropos. – Part.		
Country	Admin1	Immunity	Immunity (Hi)	Immunity (Lo)	Immunity	Immunity (Hi)	Immunity (Lo)		
Nigeria	Ondo	9.6 (8.1 - 11.0)	12.9 (10.1 - 16.0)	14.5 (11.1 – 18.6)	7.8 (6.7 – 8.7)	11.1 (8.7 – 13.8)	12.7 (9.7 – 16.3)		
Mali	Sikasso	7.1 (6.3 – 7.8)	8.3 (7.3 - 9.4)	9.0 (7.7 – 10.3)	6.1 (5.5 - 6.6)	7.4 (6.5 – 8.3)	8.0 (6.9 - 9.1)		
Guinea	Faranah	6.3 (5.9 - 6.8)	7.5 (6.8 - 8.1)	8.0 (7.3 - 8.8)	5.4 (5.0 - 5.7)	6.5 (6.0 – 7.0)	7.1 (6.4 – 7.7)		
Sierra									
Leone	Southern	6.0 (4.9 – 7.0)	7.0 (5.5 – 8.5)	7.5 (5.8–9.2)	5.1 (4.3 – 5.9)	6.1 (4.9 – 7.3)	6.6 (5.2 – 8.0)		
Cote									
d'Ivoire	Lacs	5.1 (3.8 - 6.3)	5.7 (4.1 – 7.4)	6.0 (4.3 - 8.0)	4.4 (3.4 - 5.4)	5.1 (3.8 - 6.5)	5.4 (3.9 – 7.0)		
Guinea	Nzerekore	4.3 (4.1 - 4.5)	4.8 (4.5 – 5.0)	5.0 (4.7 – 5.3)	3.9 (3.7 - 4.0)	4.3 (4.1 - 4.5)	4.5 (4.3 - 4.8)		

Sierra							
Leone	Eastern	3.9 (3.8 - 4.1)	4.3 (4.1 - 4.5)	4.5 (4.2 – 4.7)	3.5 (3.4 - 3.7)	3.9 (3.7 – 4.1)	4.1 (3.9 – 4.3)
Nigeria	Edo	2.6 (2.2 - 3.0)	2.8 (2.3 – 3.2)	2.8 (2.3 - 3.3)	2.5 (2.1 - 2.8)	2.6 (2.2 - 3.0)	2.7 (2.2 - 3.1)
Ghana	Ashanti	2.5 (1.1 - 4.6)	2.7 (1.2 – 5.1)	2.7 (1.2 - 5.4)	2.3 (1.1-4.0)	2.5 (1.1 - 4.5)	2.6 (1.1-4.8)
Sierra							
Leone	Western	2.4 (1.4 – 3.5)	2.5 (1.5 – 3.8)	2.6 (1.5 - 4.0)	2.3 (1.4 - 3.2)	2.4 (1.4 – 3.5)	2.4 (1.4 - 3.7)
Guinea	Kindia	2.3 (2.1 - 2.6)	2.4 (2.1 - 2.8)	2.5 (2.2 - 2.8)	2.2 (1.9 - 2.4)	2.3 (2.0 – 2.6)	2.4 (2.1 - 2.7)
Sierra							
Leone	Northern	2.2 (2.1 – 2.4)	2.4 (2.2 – 2.5)	2.4 (2.2 – 2.6)	2.1 (2.0 – 2.3)	2.2 (2.0 – 2.4)	2.3 (2.1 – 2.4)
Ghana	Eastern	2.2 (1.1 - 3.7)	2.3 (1.2 - 4.0)	2.4 (1.2 – 4.2)	2.1 (1.1 - 3.3)	2.2 (1.1 - 3.6)	2.2 (1.1 - 3.8)
Guinea	Kankan	2.2 (1.7 – 2.7)	2.3 (1.7 – 2.9)	2.3 (1.7 - 3.0)	2.0 (1.6 – 2.5)	2.1 (1.6 – 2.7)	2.2 (1.7 – 2.8)
Liberia	Grand Bassa	2.2 (0.4 - 7.0)	2.3 (0.4 - 8.5)	2.3 (0.4 - 9.2)	2.0 (0.4 - 5.8)	2.2 (0.4 - 7.4)	2.2 (0.4 - 8.0)
Liberia	Bong	1.8 (0.3 – 7.0)	1.9 (0.3 - 8.5)	2.0 (0.3-9.1)	1.7 (0.3 - 5.8)	1.8 (0.3 - 7.3)	1.9 (0.3 - 8.0)
Nigeria	Borno	1.5 (1.0 – 2.2)	1.6 (1.1 – 2.3)	1.6 (1.1 – 2.3)	1.5 (1.0 – 2.0)	1.5 (1.0 - 2.1)	1.5 (1.0 – 2.2)
Guinea	Labe	1.3 (0.8 – 1.9)	1.3 (0.8 – 2.0)	1.3 (0.8 – 2.0)	1.2 (0.8 – 1.8)	1.3 (0.8 – 1.9)	1.3 (0.8 – 1.9)
Nigeria	Ebonyi	1.3 (0.2 – 7.4)	1.3 (0.2 - 9.0)	1.3 (0.2 - 9.8)	1.2 (0.2 - 6.2)	1.2 (0.2 - 7.8)	1.3 (0.2 - 8.5)
Guinea	Boke	1.1 (0.7 – 1.8)	1.2 (0.7 – 1.8)	1.2 (0.7 – 1.9)	1.1 (0.7 – 1.7)	1.1 (0.7 – 1.7)	1.1 (0.7 – 1.8)

463 Table 3. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 2nd administrative level when the seroreversion rate is

464 **6%.** LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in

465 seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

			Annual Lassa Fever incidence rate (per 1,000)						
			Ser	roreverted – No Imm	unity	Seroi	reverted – Partial Im	munity	
			Seropos. – Full	Seropos. – Part.	Seropos. – Part.	Seropos. – Full	Seropos. – Part.	Seropos. – Part.	
Country	Admin1	Admin2	Immunity	Immunity (Hi)	Immunity (Lo)	Immunity	Immunity (Hi)	Immunity (Lo)	
Nigeria	Ondo	Ose	12.4 (10.1 – 13.8)	20.7 (14.1 - 28.2)	24.7 (15.9 – 35.2)	9.7 (8.1 – 10.6)	18.0 (12.1 – 25.1)	22.0 (14.1 - 32.0)	
Sierra									
Leone	Southern	Moyamba	11.2 (9.5 – 12.5)	17.6 (13.0 – 22.7)	20.7 (14.7 – 27.6)	8.7 (7.6 – 9.5)	15.0 (11.1 – 19.8)	18.2 (12.7 – 24.7)	
Nigeria	Edo	Esan West	9.7 (8.3 – 10.9)	13.2 (10.5 - 16.0)	14.9 (11.4 - 18.5)	7.9 (6.8 - 8.7)	11.3 (9.0 – 13.8)	13.0 (10.0 – 16.2)	
Sierra									
Leone	Northern	Bombali	9.5 (5.8 – 12.2)	13.1 (6.7 – 21.4)	14.9 (7.2 – 25.9)	7.6 (5.0 – 9.3)	11.2 (5.8 – 18.6)	12.9 (6.3 – 23.0)	
Sierra									
Leone	Northern	Koinadugu	9.1 (2.2 -13.1)	12.2 (2.3 – 27.0)	13.8 (2.4 – 33.6)	7.3 (2.1 – 9.9)	10.4 (2.1 - 23.8)	12.0 (2.2 - 30.6)	
Guinea	Nzerekore	Macenta	9.0 (8.2 - 9.6)	11.8 (10.5 - 13.3)	13.2 (11.6 - 15.0)	7.2 (6.7 – 7.7)	10.1 (9.0 – 11.3)	11.5 (10.0 – 13.0)	

Mali	Sikasso	Bougouni	7.0 (6.3 – 7.8)	8.3 (7.3 –9.4)	8.9 (7.8 – 10.2)	6.1 (5.5 – 6.6)	7.3 (6.5 – 8.3)	8.0 (6.9-9.1)
Guinea	Faranah	Faranah	6.3 (5.8 - 6.8)	7.4 (6.8 - 8.1)	8.0 (7.2 - 8.8)	5.4 (5.0 - 5.7)	6.5 (5.9 – 7.1)	7.0 (6.4 – 7.7)
Sierra								
Leone	Southern	Pujehun	6.3 (2.0 – 10.7)	7.4 (2.1 – 15.9)	7.9 (2.1 – 18.4)	5.4 (1.9 - 8.3)	6.5 (2.0 – 13.5)	7.0 (2.1 – 16.1)
Nigeria	Ondo	Owo	5.9 (3.6 - 8.2)	6.7 (3.9 – 10.2)	7.1 (4.0 – 11.2)	5.1 (3.3 - 6.7)	5.9 (3.5 - 8.8)	6.4 (3.6 - 9.8)
Sierra								
Leone	Eastern	Kailahun	5.6 (3.4 – 7.8)	6.4 (3.7 – 9.6)	6.8 (3.8 – 10.6)	4.8 (3.1 - 6.4)	5.6 (3.4 - 8.3)	6.0 (3.5 – 9.2)
Cote								
d'Ivoire	Montagnes	Cavally	5.3 (3.7 – 6.9)	6.0 (4.1 - 8.3)	6.4 (4.2 - 9.0)	4.6 (3.4 - 5.8)	5.3 (3.7 – 7.2)	5.7 (3.9 – 7.9)
Sierra								
Leone	Eastern	Kono	5.1 (0.2 – 12.1)	5.7 (0.2 – 20.9)	6.0 (0.2 – 25.2)	4.5 (0.2 – 0.2)	5.1 (0.2 – 18.0)	5.4 (0.2 – 22.5)
Sierra		Western						
Leone	Western	Rural	5.0 (0.1 – 12.2)	5.7 (0.1 – 21.0)	5.9 (0.1 – 25.5)	4.4 (0.1 - 9.3)	5.0 (0.1 – 18.2)	5.3 (0.1 – 22.4)
Guinea	Kindia	Kindia	4.9 (4.0 – 5.9)	5.5 (4.4 – 6.8)	5.8 (4.5 – 7.2)	4.3 (3.6 - 5.1)	4.9 (3.9 – 5.9)	5.2 (4.1-6.4)
Guinea	Nzerekore	Gueckedou	4.6 (4.3 - 5.0)	5.1 (4.7 – 5.6)	5.4 (4.9 – 5.9)	4.1 (3.8 - 4.4)	4.6 (4.3 – 5.0)	4.9 (4.5 - 5.3)
Guinea	Nzerekore	Lola	4.4 (3.8 - 5.1)	4.9 (4.2 – 5.7)	5.1 (4.3 - 6.0)	3.9 (3.5 - 4.4)	4.4 (3.8 - 5.1)	4.6 (3.9 – 5.4)

Cote								
d'Ivoire	Montagnes	Guemon	4.4 (2.3 - 6.9)	4.8 (2.4 - 8.3)	5.1 (2.4 - 8.9)	3.9 (2.2 – 5.8)	4.4 (2.2 - 7.2)	4.6 (2.3 - 7.9)
Guinea	Nzerekore	Yamou	4.2 (3.7 – 4.7)	4.6 (4.0 – 5.3)	4.8 (4.2 – 5.5)	3.8 (3.4 - 4.2)	4.2 (3.7 – 4.7)	4.4 (3.8 - 4.9)
Sierra								
Leone	Eastern	Kenema	3.9 (3.7 – 4.1)	4.3 (4.0 – 4.5)	4.5 (4.2 – 4.7)	3.5 (3.4 – 3.7)	3.9 (3.7 – 4.1)	4.1 (3.8 – 4.3)

- 468 The age-specific infection histories calculated using the projected and ensemble FOI estimates can also
- 469 be used to calculate annual LF incidence rates for specific age groups. LF incidence rates decrease with
- 470 age as the likelihood of a previous infection and at least partial protection from infection and disease
- 471 increases (Figure 6).

472



473



administrative units with the highest incidence. Incidence calculated using projected FOI estimates from

476 LF case data and estimated reporting probabilities and assuming a seroreversion rate of 6%, seropositive

- 477 individuals have partial protection from reinfection and disease (RR=0.53), and seroreverted individuals
- 478 are partially protected (RR=0.36) from reinfections and disease. Boxes represent interquartile range

479 (IQR) and lines the 95% prediction interval.

480 Interannual variability in incidence

481 The 1,000 samples from the posterior distribution of the projected FOI estimates incorporate both the 482 uncertainty and the interannual variability in our FOI estimates and the corresponding annual LF 483 incidence rates. Figure (7) provides an example of the variability in LF incidence rates (per 1,000) for the 484 nine highest incidence admin2 units under a scenario where the seroreversion rate is 6%, seroprotected 485 individuals have a relative risk = 0.36 of developing LF if infected, and seroreverted individuals are also 486 partially susceptible to reinfection and disease (relative risk = 0.53). The variation in LF incidence rates is 487 highest for locations where FOI was estimated from LF case data and reporting probabilities only (no 488 serology data) because these estimates incorporate uncertainty in reporting probabilities in addition to 489 interannual variability. Locations where FOI estimates were informed by serology data, such as Macenta and Faranah Districts in Guinea and Sikasso District in Mali, have lower uncertainty. However, even in 490 491 these locations, the estimated annual LF incidence rate can vary by 10-50% from year-to-year. For 492 example, the narrowest estimated range in annual LF incidence is in Faranah District, Guinea with a 493 median annual incidence of 7.0 per 1,000 (95% Crl: 6.4-7.7), where 95% of years would be expected to 494 be within +/- 10% of the median value. Esan West LGA in Edo State, Nigeria has a median LF incidence 495 rate of 13.0 per 1,000 (95% CrI: 10.0-16.2), with variability of +/- 25% from the median. An example of a 496 location with a high uncertainty and interannual variability is Ose LGA in Ondo State, Nigeria which has a 497 median annual LF incidence rate of 22.0 per 1,000 (95% Crl: 14.1-32.0) with variability of approximately 498 +/- 50%.

499 Seasonality

Reported LF cases in Nigeria and Liberia, and to a lesser extent in Sierra Leone, show a clear seasonal
pattern with a peak in cases in January to March (Figure 8). Liberia also shows a secondary peak later in
the year, although this may be part of the January peak in cases. In Sierra Leone, LF cases peak in March,
but there appears to be considerable transmission throughout the year.





Figure 7. Posterior distribution of annual Lassa fever (LF) case incidence rates in the nine highest admin2 units. LF incidence estimates are based on projected FOI estimates from LF case data and reporting probabilities. Results presented are for a scenario with 6% seroreversion rate, partial protection against reinfection and disease in seropositive individuals (relative risk = 0.36), and partial protection against reinfection or disease among seroreverted individuals (RR = 0.53). The red dashed line is the median of the posterior distribution.

518



Figure 8. Seasonality of LF incidence in (A) Nigeria, (B) Liberia, (C) Sierra Leone, and (D) averaged across
 these three countries. Blue line represents a generalized additive model with a cyclical cubic regression
 spline fit to the weekly fraction of annual cases (grey represents the 95% confidence interval).

524 Discussion

525	Using a modeling framework that incorporated LF serology, case, and death data, we found considerable
526	spatial variation in LASV spillover and LF incidence across West Africa, with the highest incidence rates in
527	areas within Nigeria, Sierra Leone, and Guinea. We also estimate that as few as 0.2% of LASV infections
528	are captured by current surveillance systems. These results represent the most extensive and
529	geographically detailed estimates of LF surveillance and incidence across the entire endemic range in
530	West Africa to date. Our LF incidence estimates were sensitive to assumptions about the duration and
531	strength of infection-induced immunity. LF incidence rates were particularly sensitive to the rate of
532	seroreversion among previously infected individuals because this value affects both susceptibility to
533	reinfection and the interpretation of serology data. Our spatial LF incidence rate estimates, along with
534	the interannual and seasonal variability in these estimates, could be used to target high incidence areas
535	suitable for inclusion in a vaccine trial and estimate expected trial event rates. However, the
536	uncertainties in our LF incidence estimates highlight critical knowledge gaps regarding the number of
537	asymptomatic and mild LASV infections that go undetected and the extent to which these infections
538	provide long-lasting immunity.
539	Our estimates of LF incidence rates indicate that there are few 1 st or 2 nd level administrative districts
540	where the predicted attack rate would be at least 1% as is desired for vaccine field trials. Our estimates
541	assumed that 20% of LASV infections are symptomatic, as frequently reported. However, if substantially
542	fewer than 20% of infections are captured by active syndromic surveillance, as has initially been
543	reported for the Enable study, then none of these districts would be likely to reach an LF attack rate of
544	1%. ¹⁵ Therefore, ensuring sufficient statistical power may require a large increase in the number of
545	individuals enrolled in a field trial. One alternative to increasing the size of the study population would
546	be to use protection against infection as a primary endpoint instead of protection against symptomatic
547	disease. Due to the high number of asymptomatic infections, active monitoring for seroconversion—

while more difficult and costly than symptom-based surveillance methods—would increase the number
of expected endpoints without increasing the size of the study population. Another option would be to
adopt a responsive trial design that employed ring vaccination or a similar strategy to focus study efforts
on locations with active transmission. Given the focal nature of LF spillover to humans, and the
substantial interannual and seasonal variation in incidence, such a strategy would ensure that areas of
active transmission are targeted.^{23,40,46}

554 Trial site selection also needs to account for the baseline seroprevalence in a target population as that 555 will influence the fraction of the population that is susceptible to infection. Locations with high baseline 556 seroprevalence may experience few LF cases even if LASV is actively circulating in the rodent population. 557 However, there is considerable uncertainty about the duration of immunity to LASV, and several studies suggest that seroreversion is relatively common.^{23,24,76} Assumptions about the seroreversion rate had 558 559 the largest impact on estimated LF incidence among the different immunological scenarios included in 560 our analysis. Without seroreversion, our FOI estimates were too low for the resulting annual LF 561 incidence rates to exceed 10 per 1,000 (1%) anywhere within the study region. Further results from the 562 longitudinal serology samples from the Enable study should help refine our understanding of 563 seroreversion rates and whether they vary by location or age.

564 The level of protection against reinfection and disease among both seropositive and seroreverted 565 individuals also influenced expected LF incidence rates in our model, with higher levels of protection 566 against disease resulting in lower expected incidence rates. The different scenarios explored in our 567 model could be leveraged to select the most plausible scenario for estimating event rates in a particular 568 site and target population. This model can also be used to explore how LF incidence rates vary by both 569 age and serostatus under different assumptions regarding how serostatus affects susceptibility to 570 (re-)infection and disease, which can help to inform selection of a target population and trial size 571 calculations. Results from the Enable study will also help refine future model scenarios regarding the
role of immunity and serostatus, as the study will report relative LF incidence rates among individuals
who were seropositive or seronegative at baseline (or in the previous sampling period) and may also be
able to capture the reinfection and LF incidence rates among individuals who serorevert over the course
of the study.
Our model projections represent the most extensive and geographically detailed estimates of LF

577 surveillance and incidence across the entire endemic range in West Africa to date. Previous modeling

578 studies have generated fine-scale maps of the likely distribution of LASV, but have not estimated LF

579 incidence rates or seroprevalence in the human population.^{26,28,51} Basinski et al. (2021) modeled LASV

risk in rodents and then fit a regression model of this risk measure against historical seroprevalence data

581 to generate fine-scale estimates of LASV seroprevalence in the human population.²⁵ However, their

582 study did not incorporate LF incidence data or account for certain epidemiological features of LF in

583 generating these estimates. Our projected FOI estimates and modeled annual LF incidence rates indicate

that Sierra Leone, southern Guinea near the border with Sierra Leone and Liberia, and a few high

585 incidence regions within Nigeria would likely yield the highest LF case incidence rates during a vaccine

trial. Comparisons of our estimates at the 1st and 2nd administrative levels show that there is

587 considerable spatial heterogeneity among different admin2s within the same 1st administrative unit

588 (particularly in Nigeria, Guinea, and Mali), and therefore predictions from the 2nd administrative level

are likely to be more useful for site selection.

The 2nd administrative level FOI estimates that were projected from LF case data and reporting probabilities appear to be more accurate than the FOI estimates from our ensemble model that used spatial covariates to improve model predictions in areas lacking data, particularly in areas that are projected to have the highest incidence. The ensemble model smoothed over the spatial heterogeneity in FOI to an extent that lowered the incidence rate in some regions with a high number of reported cases and deaths, particularly in Edo and Ondo states in Nigeria. Therefore, at present, the projected FOI

596 estimates likely provide more reliable estimates for field trial site selection than the estimates from the 597 ensemble model. Further model refinements, including model selection techniques to determine the most influential spatial covariates, and further model validation using serology data from the literature 598 599 and forthcoming Enable results could improve the ensemble model predictions. However, regression 600 analyses and ensemble modeling methods are most useful for predicting incidence where data is sparse 601 and the relationship between the response variable (incidence) and the explanatory variables is strong. 602 There is still a lot of uncertainty about what conditions distinguish areas with high LASV spillover rates 603 from areas with similar environmental conditions and where Mastomys spp. are present, but spillover is 604 rare or nonexistent. Hopefully additional field studies and serological surveys will help explain these 605 discrepancies, but at present we lack the ability to predict the occurrence of LF at a fine spatial scale 606 outside of the well-documented hotspots of transmission. In the absence of this ability, our admin2 607 incidence estimates could help identify broader regions to target for vaccine trials, and baseline serology 608 surveys can be conducted at the local level to confirm LASV spillover in the area. In particular, evidence 609 of past infection in younger children would indicate recent transmission.

610 Our modeling framework did incorporate estimation of country specific LF case and death reporting 611 probabilities, but it also seems unlikely that areas within the study region that haven't reported any LF 612 cases or deaths have as high a burden of LF as the known hotspots in Nigeria, Sierra Leone, Guinea, and 613 Liberia. The burden of LF outside of the known hotspots is an important outstanding question, but it is 614 likely that observed spatial patterns of reported LF cases and deaths reflect at least some important 615 differences in the spatial distribution of the disease. Although mild and moderate LF cases are difficult to 616 distinguish from other febrile illnesses such as malaria, severe LF cases requiring hospitalization have 617 been associated with nosocomial outbreaks in Nigeria, Sierra Leone, and Liberia, but not in other areas 618 West Africa.^{77–79} A seroprevalence study in multiple locations within Ghana, and preliminary 619 seroprevalence results from the Enable site in Benin also suggest that transmission is lower in these

620	countries than it is in the known hotspots for transmission. ⁵¹ However, high seroprevalence were
621	recently observed in southern Mali, suggesting that there may be undocumented areas of LF incidence
622	outside of the historical hotspots. ^{80,81}
623	Model limitations
624	Despite recent efforts to prioritize the study of LF, there are still many unknowns, which limit the
625	predictive power of our model. LF incidence rates vary significantly based on many confluent factors,
626	and the limited number of longitudinal and broad scale studies makes it difficult to draw significant
627	conclusions about the risk of LF in a particular time and place. Our model does not account for non-
628	epidemiological considerations that may influence site selection, such as the strength of the existing
629	local or national health infrastructure system, political stability, or cultural barriers to trial
630	implementation. However, the model results can be used to rank potential trial sites by expected LF
631	incidence rates and seroprevalence (e.g., expected serostatus by age group), and then other factors can
632	be used to select appropriate trial sites from locations with suitable characteristics.
633	The current model also cannot estimate the geographical variation in expected LF incidence rates within
634	a given 2 nd administrative area. Past serology studies in Guinea and Sierra Leone, and preliminary results
635	from the Enable study, show that seroprevalence rates can vary significantly from village to village
636	within the same state or district. ^{23,40,46} However, the identification of risk factors associated with small-
637	scale variations in seroprevalence, infection attack rates, or LF incidence have been inconsistent, limiting
638	our ability to predict high incidence areas within a given administrative region. The Enable study will
639	provide some additional context on this finer-scale heterogeneity in attack rates and incidence due to
640	the large sample size and the relatively high number of villages sampled. However, the targeted criteria
641	used for site selection may limit our ability to extrapolate the study results beyond these study sites.
642	Variation in our estimated LF incidence rates for a given location results from a combination of

643 parameter uncertainty and interannual variability in reported LF cases and deaths. Longitudinal

- 644 serological or incidence data was insufficient to explicitly estimate interannual variability across the
- 645 study area.
- 646 Conclusions

647	Our modeling framework enabled us to leverage multiple data sources to estimate LF incidence at the
648	2 nd administrative level across West Africa. Expected incidence varied considerably and showed marked
649	geographic variation across spatial scales. Although an ensemble of regression models showed
650	moderate success at predicted incidence based on environmental and socioeconomic data, it tended to
651	underestimate incidence in high-risk regions, which are the most relevant for disease control and
652	vaccine trial planning. Our work highlights the importance of ecological and immunological factors and
653	underscores large uncertainties in our understanding of LF epidemiology. Our findings emphasize the
654	need for more prospective data (e.g., the Enable study), particularly regarding the fraction of infections
655	that are detectable by syndromic surveillance and the duration of infection-induced immunity. At the
656	scales considered, very few locations in West Africa are predicted to experience LF incidence at the
657	levels needed to conduct a vaccine efficacy trial (annual incidence of at least 10 per 1000). Designs
658	would need to accommodate low disease incidence (e.g., preparatory observational studies and active
659	monitoring for asymptomatic infections) or look to prospectively enrich the trial population with at risk
660	individuals (e.g., ring vaccination). Our modeling framework is designed to be updated iteratively with
661	future serological survey data and LF surveillance data. Our estimated incidence rates are intended to
662	assist with trial site selection, sample size calculations, and the decisions regarding the appropriate
663	target population and primary endpoint.

664 Acknowledgements

- 665 The authors thank CEPI for insights into current planning considerations for Lassa fever vaccine trials and
- an overview of the preliminary results from the ENABLE study. We thank Melissa Wynn, Carrie Mills,
- 667 Kevin Sprurgers, and Lovelyn Charles at Emergent Biosolutions for help with coordinating research
- 668 efforts.
- 669 Author Contributions
- 670 Conceptualization: SMM, NED, STS
- 671 Data Curation: SMM, ER, SMG
- 672 Formal Analysis: SMM
- 673 Funding Acquisition: STS
- 674 Investigation: SMM
- 675 Methodology: SMM, NED, STS
- 676 Project Administration: SMG, STS
- 677 Resources: SMM
- 678 Software Programming: SMM
- 679 Supervision: STS
- 680 Validation: SMM
- 681 Visualization: SMM, ER
- 682 Writing Original Draft Preparation: SMM, ER
- 683 Writing Review & Editing: SMM, ER, SMG, NED, STS

685 Supporting Information

- 686 S1 Appendix
- 687 Model Details
- 688 **1.** Estimating the Force of Infection from Serology Data

689 For administrative units with serology data binned by age group, we calculated the likelihood of the FOI

(λ) based on the number of individuals between ages a_1 and a_2 (the upper and lower bounds of the age

group) who tested positive, $P(a_{1:2})$, out of the total number sampled, $T(a_{1:2})$. The likelihood was

692 calculated for each age between a_1 and a_2 assuming a binomial distribution, $P(a_{1:2}) \sim$

693 Binomial($T(a_{1:2}), p(a)$) where p(a) is the probability that an individual was seropositive as determined by

equation (2). We then took a weighted average of the likelihood for each age group, with the weighting

determined by the proportion of the population in that administrative unit in each age within the age

group. We calculated the likelihood of the overall FOI (λ_i) in administrative unit *i* by summing the logs of

the binomial probabilities of $P_i(a_{1:2})$ across all age groups in a given seroprevalence dataset. The

698 likelihood of a given FOI (λ_i) for each administrative unit *i* was calculated across a range of values

699 between 10⁻⁶ and 10¹. We then fit a gamma distribution using the *optim* function in R to estimate shape

and scale parameters representing the mean and variance in FOI (λ_i), and these parameters were used

- as inputs to the subsequent steps in the modeling framework.
- 702 **2.** Estimating Country-specific Reporting Fractions

For each administrative unit where the FOI was estimated from serological data in the previous step, we estimated the fraction of LF infections from 2010-2023 that went unreported based on the discrepancy between reported LF cases and deaths and the number of infections predicted by the FOI estimates from those sites under the three different seroreversion scenarios. We assume that all individuals within an administrative unit are at risk of LASV infection and that each individual has the potential to fall into

708 one of three categories during the study period: an observed LF case, an observed LF death, or 709 unobserved. The unobserved category includes both individuals who were not infected and individuals 710 who had an unobserved LASV infection (either because it was an asymptomatic infection or was an LF 711 case/death that was not reported). We therefore modeled the distribution of person-years from 2010-712 2023 across these three categories: observed deaths, D; observed cases, C; and the total unobserved 713 person-years, N. For administrative unit i, the total unobserved person-years, N_i, is calculated as $N_i = Y_i - Y_i$ 714 $C_i - D_i$, where $Y_i = \Sigma Pop_i$ is the sum of the annual population sizes from 2010-2023. The probability that a 715 person of age a in year y would die from LF and be reported as such was,

716
$$\Pr(reported \ death, a \ | \lambda_i, U_i, \rho_D, \pi) = (1 - p(a)) \frac{\lambda}{\lambda + \pi} (1 - e^{-(\lambda + \pi)}) (1 - U_i) \rho_D, \quad (A1)$$

717 where U_i is the proportion of infections that are unobserved in location i and ρ_D is the proportion of 718 observed infections that result in death. Equation A1 represents the probability that an individual was 719 susceptible at time y, and subsequently becomes infected in year y (based on the FOI, λ) and 720 experienced an infection that was both observed and resulted in death. The probability of a reported 721 case was the same as equation (A1) but with ρ_D replaced by $1 - \rho_D$. The probability of an unobserved 722 person-year, $Pr(unreported \ person \sim year, a \mid \lambda_i, U_i, \pi)$, takes into account the multiple ways in which 723 a person-year would not result in a reported death or case, including currently being immune due to a 724 past infection, by not being infected during the study time period from 2010-2023, or by being infected 725 in year y but not being reported. From Pr(reported death), Pr(reported case), and Pr(unreported person-726 year) we calculate the probability of D_i , C_i , and N_i among Y_i total person-years, $Pr(D_i, C_i, N_i | \lambda_i, U_i, \rho_D)$, 727 using a multinomial distribution. Given estimates of λ_i from step 1, we used this distribution to estimate 728 the parameter U_i for each i, and country-specific values for ρ_D . The log likelihood of U_i and ρ_D was 729 calculated by summing the logs of the probabilities from $Pr(D_i, C_i, N_i | \lambda_i, U_i, \rho_D)$ assuming 730 noninformative priors between 0 and 1 for all U_i and a beta-distributed prior for ρ_D with shape

parameters 2.05 and 6.85. The posterior distributions of the parameters were then sampled using the
BayesianTools package in R.

733 To extrapolate reporting fractions beyond the few administrative units with both serological and 734 case/death data, we fit a Dirichlet distribution to the posterior predictions of the proportions of 735 infections that result in a reported death, a reported case, or an unreported infection. For each draw j 736 from the posterior, the proportions of reported deaths, reported cases, and unreported infections were calculated respectively as $(1 - \overline{U}_i)\rho_{D,i}$, $(1 - \rho_{D,i})$, and \overline{U}_i ; with $\overline{U}_i \rho_{D,i}$ representing the country-737 specific averages across all sites *i* within a country for each draw *j* from the posterior distribution. The 738 739 corresponding Dirichlet parameters associated with reported cases, reported deaths, and unreported 740 infections were α_D , α_C , and α_U . We estimated these Dirichlet parameters by maximum likelihood using 741 the optim function in R, treating posterior predictions of the proportion of infections that result in a 742 reported death, a reported case, or an unreported infection as data points drawn from the Dirichlet distribution being fitted. 743

744 **3.** Estimating LASV spillover rates

For each administrative unit we next estimated the total number of annual infections, I_{ii} based on the reported LF cases and deaths from 2010-2023 along with the estimated reporting probabilities from the previous step. The likelihood of a given number infections, I_{ii} in administrative unit *i* was calculated using the Dirichlet-multinomial probability of obtaining the reported deaths, D_{i} , and reported cases, C_{i} , and I_{i} - $D_{i} - C_{i}$ unobserved infections following I_{i} draws of those categories according to Dirichlet-distributed probabilities with parameters α_{D} , α_{C} , and α_{U} from step 2:

751
$$L(I_i|C_i, D_i, \alpha_D, \alpha_C, \alpha_U) = \Pr(D_i, C_i, I_i - D_i - C_i|I_i, \alpha_D, \alpha_C, \alpha_U).$$

We normalized the likelihoods from this equation across all values of *I_i* to obtain posterior probabilities
of each *I_i*, which we used to obtain a set of posterior samples of *I_i* for each admin1 and admin2 unit.

754 **4.** Projecting the Force of Infection from estimated LASV spillover rates

755	For each administrative unit where LASV spillover infections were estimated from LF case/death data,
756	we projected the underlying FOI that would correspond to the estimated infection rate. The projected
757	FOI, for each administrative unit <i>i</i> was obtained by minimizing the difference between the number of
758	infections, I, estimated in the previous step and the expected number of infections arising from a given
759	FOI in the reverse catalytic model from equation (2) using the optim function in R. This resulted in a
760	posterior distribution of FOI _i for each admin1 and admin2 unit.
761	5. Estimation of Population-level Infection Histories
762	The FOI projections generated from serology and case data in step 4 were next used to simulate
763	population-level infection histories for each admin1 and admin2 unit. For the FOI projections, we drew
764	1000 samples for each administrative unit from the posterior distribution using the estimated shape and
765	scale parameters from the gamma distribution estimated in step 1. For each value $FOI_{i,j}$, (where j=1000
766	is the sample set) we computed the proportion of the population in administrative unit <i>i</i> that had been
767	infected by age <i>a</i> using the catalytic model in equation (1), and the proportion of the population
768	seropositive at age <i>a</i> using the reverse catalytic model in equation (2).

769 **6.** Estimating LASV Infection and LF Attack Rates

The population-level infection histories and FOI estimates were then used to compute the expected number of infections in each administrative unit i. We examined several different scenarios regarding the risk of seropositive or seroreverted individuals becoming reinfected and developing LF as described in the *Methods* section of the main text. The expected annual number of infections in administrative unit *i* were calculated from the FOI_{*i*} using the reverse catalytic model for each of the 18 different scenarios at both the admin1 and admin2 levels. The number of infections was multiplied by the

symptomatic probability (20%) to obtain an estimate of the expected number of LF cases in each

- 777 administrative unit.
- 778 Modeling the Force of Infection from Covariate Data

779 The estimation of LASV spillover rates and the projection of the FOI from these spillover rates was 780 performed for all admin1 and admin2 administrative units within the study region. However, LF cases or 781 deaths have been reported in <50% of administrative units within the region (Figure 1), and infection 782 estimates for these administrative units without any reporting are contingent on our estimated 783 underreporting probabilities. In addition, there is also a large degree of uncertainty in the true spillover 784 rate in administrative units that have reported only a small number of LF cases due to the large 785 proportion of asymptomatic infections and low reporting probabilities. Therefore, we used several 786 statistical models to explore the relationships between our FOI_i estimates from step 4 and several key 787 spatial covariates (Supplemental Table S2). These models were fit to the projected FOI_i estimates from 788 administrative units with either serology data or reported LF case/death data (N=77 of 164 admin1s, 789 N=372 of 1375 admin2s). The fitted models were then used to predict FOI in the administrative units 790 with no serology or case data. Given that we have a relatively small dataset and high uncertainty in our 791 projected FOI estimates, we considered eight different models, as well as a null model with a single FOI 792 estimated across all administrative units. The first two models were linear regression models with or 793 without two-way interaction terms between covariates. We also considered four different Gaussian 794 Markov random field (GMRF) models: two with no covariates and two with linear effects of the 795 covariates. GMRF models use a minimum mean squared error linear prediction with spatial covariance 796 for spatial prediction or interpolation⁸². The GMRF models with or without linear effects for the 797 covariates were run at two spatial resolutions: a low resolution (k=10 free parameters for admin1 and 798 k=25 for admin2) or high resolution (k=40 for admin1 and k=100 for admin2). The seventh model was a

random forest model implemented in R with the *randomForest* package. The eighth, and final, model
was a boosted regression model implemented in R with the *abm* package.

801 For each of the models we took 1000 samples from the posterior distributions of FOI_i from step 4 and

regressed log₁₀ FOI against the covariates (where applicable), resulting in 1000 separate fits per model.

803 The predicted values for both the fitted and unfitted administrative units from each model were then

804 treated as point estimates to construct a set of 1000 posterior samples of FOI_i for each administrative

805 unit and each model.

806 Ensemble model

807 For each seroreversion scenario, we generated an ensemble model projection of FOI in each admin1 or

admin2 using a form of stacked generalization⁸³. Stacked generalization treats the eight statistical

809 models as being at one level and uses the first-level models to generate a higher-order model that

810 weights the predictions of the first-level models into its own prediction. The performance of each first-

811 level model was assessed using a ten-fold cross-validation technique, with 90% of the data partitioned

812 into the training set to fit the model, and the remaining 10% withheld for model validation. This process

813 was performed ten times, with a different 10% of the dataset withheld for validation each time. Model

814 performance was then assessed based on the model predictions on the withheld data and ensemble

815 weights for each model were calculated based on relative model performance.

816

818 S1 Results

819 **1. Statistical and ensemble model results**

820	At the admin1 level, the most important covariates in the random forest model were longitude, travel
821	time to the nearest urban center, and the Healthcare access and quality index (HAQ) (Table S3). The
822	most influential covariates in the boosted regression model were longitude, travel time to the nearest
823	urban center, and the estimated probability of LASV presence in Mastomys natalensis (Table S4). At the
824	admin2 level, the most important covariates in the random forest model were longitude, HAQ, and the
825	2 nd precipitation PC (Table S5). The covariates with the largest t-values in the linear model with
826	interactions were longitude, the fraction of forest loss since 2000, and percentage of tropical habitat
827	(Table S6).
828	The performance of the model predictions on data held out of the regression for model validation was
829	much lower for the 1 st administrative level, with random forest providing the best fit to the testing data
830	(r ² =0.32), suggesting that the models are overfitting to the training dataset (Figure S5). The cross-
831	validation performance of most regression models was better at the 2 nd administrative unit, with the
832	random forest model providing the best fit (r ² =0.76), and the boosted regression and GMRF models with
833	and without covariates all maintaining an r ² >0.70 (Figure S6). The low ratio of data points per covariate
834	at the admin1 level may explain the poor cross-validation performance relative to the admin2 level
835	(N=77 for admin1 vs. N=372 for admin2).

836 Ensemble model

Our ensemble model consisted of a weighted combination of the FOI predictions of each individual statistical regression model, along with a noise term. Each model weight was calculated based on its negative marginal log likelihood in ten-fold cross-validation. Assuming a 6% seroreversion rate, the highest model weight for the admin1 ensemble model was the random forest model (43.7%), followed

by the boosted regression model (35.1%), the high resolution GMRF with covariates (9.9%), the high resolution GMRF without covariates (6.0%), and the low resolution GMRF with covariates (5.2%). For the admin2 ensemble model the model weights of at least 5% in decreasing order were: the random forest model (46.3%), the high resolution GMRF with covariates (15.1%), the low resolution GMRF without covariates (13.7%), the high resolution GMRF without covariates (11.5%) and the boosted regression model (5.8%).

847 Ensemble model estimates of FOI at the 1st administrative level show a similar spatial pattern and

848 magnitude to the projected FOI estimates (Figure 4A), with predicted high FOI areas in Sierra Leone,

849 Guinea, and southern Nigeria (Figure S9A). However, there are admin1 units that did not report any LF

cases or deaths from 2010-2023, and therefore had low projected FOI values, but are predicted by the

ensemble model to have high FOI values. The ensemble model FOI estimates at the 2nd administrative

unit (Figure S9B) show much less spatial heterogeneity than the projected FOI estimates from LF case

853 data and reporting probabilities (Figure 4B). This largely results from the higher weighting of the GMRF

models, which include spatial smoothing (45.7% combined among the four GMRF models). This spatial

855 smoothing results in lower FOI estimates in the few projected Nigerian hotspots, and lower within- and

among-country variation in FOI estimates overall.

857

1. Table S1. Papers selected for in-depth literature review.

Title	Author	Study topic	Publication	Stud	Country	Sampl	Pop details	lgG	lgM	PCR	Symp	Seasonalit	Rainfa	Vegetatio	Risk factors
			date	у		e size		pos	pos	pos	. rate	y (Y/N)	П	n (Y/N)	
				date									(Y/N)		
				S											
Quantifying the	Akhmotzhan	Environmont	2019		Nigoria			22	22	n 2	n 2	n 2	v	22	LE conconstitution
	. 131	/	2019		Nigeria			IIa	IId	na	IIa	IIa		IId	LF seasonality not
seasonal drivers	ov et al ³¹	/ seasonality													associated w
of transmission															number of
for Lassa fever in															infected rodents,
<u>Nigeria</u>															but yes w rainfall
A seasonal model	Barua et al ⁸⁴	Environment	2021	2018	Nigeria		Edo and	na	na	na	na	na	na	na	
to assess		/ seasonality		-			Ondo states								
intorvontion		,,		2020											
intervention				2020											
strategies for															
preventing															
<u>periodic</u>															
recurrence of															
Lassa fever															
Risk Maps of Lassa	Fichet-Calvet.	Environment	2009	1963	All			na	na	na	na	na	Y	N	Rainfall. not
Equar in Wast	Pagare ⁵¹	/ conconality			publicho										vogotation
rever in west	NUgers	/ seasonality		-	publishe										vegetation
<u>Atrica</u>				2007	d Lassa										
					cases										

Mapping the	Mylne et al ⁵²	Environment	2015	1963	All			na	na	na	na	na	Y	Y	Vegetation, land
zoonotic niche of		/seasonality		-	publishe										surface temp, rat
Lassa fever in				2014	d Lassa										dist, elevation,
<u>Africa</u>					cases										potential
															evapotranspiratio
															n
Geographical	Redding et	Environment	2021	2012	Nigeria			na	na	na	na	na	Y	Y	Low
drivers and	al ⁵	/ seasonality		_	Ū										precipitation.
climate-linked		,,		2019											vegetation
				2019											dealine
<u>aynamics of Lassa</u>															aecline
fever in Nigeria															
Annual Incidence	Safronetz et	Incidence	2017	2015	Mali	532	Three	na	No significant risk						
of Lassa Virus	al ⁷			-			villages in								factors
Infection in				2016			southern								
Southern Mali							Mali								
							(Soromba,								
							Bamba, and								
							Bazana):								
							follow-up to								
							2015 study								
							from Sogoba								
							et al								

Lassa Virus	Bangura et	Rodent epi	2021	2014	Sierra	1490	1490 small	8.1%	na	1%	na	Y	na	na	Significant
Circulation in	al ⁵⁸			-	Leone		mammals in								seasonal
Small Mammal				2016			6 villages in								variation, 40% at
Populations in Bo							Bo District;								the start of rainy
District, Sierra							357 M								season; trapping
<u>Leone</u>							natalensis,								success highest in
							345 P								farming
							rsotratus,								communities,
							261 R rattus								most trapping
															inside houses
<u>Geographic</u>	Safronetz et	Rodent epi	2013	2007	Mali	511	Villages	6.8%	na	8%	na	na	na	na	
Distribution and	al ²⁹			-			across Mali;								
<u>Genetic</u>				2012			715 total,								
Characterization							511 M nat								
<u>of Lassa Virus in</u>															
Sub-Saharan Mali															
Lassa Serology in	Fichet-Calvet	Rodent epi	2014	2002	Guinea	1551	17 villages in	18.0	na	10%	na	N	na	na	No seasonality,
<u>Natural</u>	et al ⁵⁵			-			different	%							no sex
Populations of				2004			vegetation								
Rodents and							zones								
<u>Horizontal</u>															
Transmission															

Fluctuation of	Fichet-Calvet	Rodent epi	2007	2003	Guinea	553	Northern	na	na	15%	na	Y	na	na	Highest in rainy
Abundance and	et al ⁶⁵			-			Guinea;								season
<u>Lassa Virus</u>				2005			1123 total								
Prevalence in							animals, 553								
<u>Mastomys</u>							M natalensis								
natalensis in															
<u>Guinea, West</u>															
<u>Africa</u>															
Sequence	Leski et al ⁸⁵	Rodent epi	2015	2009	Sierra	681	199 M	na	na	18%	na	na	na	na	
Variability and					Leone		natalensis at								
<u>Geographic</u>							13 locations								
Distribution of							in 3 districts								
Lassa Virus, Sierra							in the south								
<u>Leone</u>							and east of								
							SL								
Prevalence of	Agbonlahor	Rodent epi	2017	2015	Nigeria	1500	Edo (North:	na	na	11-	na	na	na	na	
Lassa virus among	et al ⁵⁹			-			100, South:			87%					
rodents trapped				2016			200, Central:								
in three South-							200) Delta								
South States of							(N: 200, C:								
<u>Nigeria</u>							200, S: 100)								
							and Bayelsa								
							(W: 200, C:								

							200, E: 100)								
							states								
Increased	Happi et al ⁸⁶	Rodent epi	2022	2018	Nigeria	942	Ondo and	na	na	41.2-	na	na	na	na	
Prevalence of				-			Ebonyi; 942			72.1					
Lassa Fever Virus-				2020			includes not			%					
Positive Rodents							just M								
and Diversity of							natalensis								
Infected Species							(did not								
Found during							provide								
<u>Human Lassa</u>							number)								
Fever Epidemics															
<u>in Nigeria</u>															
Lassa Fever in	Demby et al ⁵⁴	Rodent epi	2001	1996	Guinea	884	444	11.0	na	na	na	Y	na	Y	Relates animal
<u>Guinea: II.</u>				-			households;	%							positivity w
Distribution and				1997			1616 total								humans by
Prevalence of							rodents, 884								region/forestatio
<u>Lassa Virus</u>							Mastomys								n
Infection in Small															
Mammals															
Widespread	Olayemi et	Rodent epi	2018	2011	Nigeria	906	M natalensis	1-	na	na	na	N	na	na	Didn't find
arenavirus	al ⁵⁶			-			in 11 sites in	52%							evidence of
occurrence and				2015			Nigeria								seasonality but
seroprevalence in															

small mammals,															also small sample
<u>Nigeria</u>															size
Predicting the	Klitting et al ⁸⁷	Rodent epi	2022		Africa			na	na	na	na	na			
evolution of the															
Lassa virus															
endemic area and															
population at risk															
over the next															
decades															
Lassa Virus	Sogoba et	Serology	2016	2015	Mali	600	Three	33.2	0.7%	na	na	na	na	na	Higher age, no
Seroprevalence in	al ⁴⁷						villages in	%							sex
<u>Sibirilia</u>							southern								
<u>Commune,</u>							Mali								
<u>Bougouni District,</u>							(Soromba,								
Southern Mali							Bamba, and								
							Bazana)								
Lassa fever in	Tobin et al ⁴⁸	Serology	2015		Nigeria	177	Edo. Esan	58.2	1.1%	na	na	na	na	na	No assn sex.
Nigeria: Insights					0.		West I GA:	%				-			education, social
into							50								class (IgG): lower
soroprovalanca							boussholds								
seroprevalence							nousenoids,								in age < 20 and
and risk factors in							1//								unmarried
rural Edo State: A							individuals								
pilot study_															

Seroepidemiologic al study reveals regional co- occurrence of Lassa- and Hantavirus antibodies in Upper Guinea,	Klempa et al ⁴¹	Serology	2012	2004	Guinea	253		40.3 %	2.8%	0%	na	na	na	na	No assn sex or month of collection (May vs Oct), lower seroprevalence in youngest and oldest
West Africa															
Space-Time	Shaffer et al ⁸	Serology	2021	2012	Sierra	3277	tested at	33.6	31.5	na	na	na	Y	Y	Temp,
Trends in Lassa				-	Leone		KGH LF Lab	%	%						precipitation, and
Fever in Sierra				2019											presence of
Leone by ELISA															pastures main
Serostatus, 2012–															factors for
<u>2019</u>															ecological
															suitability in M
															natalensi; <20%
															pastureland and
															temps < 25 C not
															suitable
Rodent-borne	Nimo-Paintsil	Serology	2019		Ghana	657	7 northern	5.2%	na	na	na	Ν	na	Y	No seasonality,
infections in rural	et al ⁵⁰						villages								no sex, no age
							(savannah								

Ghanaian farming							woodland)								
<u>communities</u>							and 3								
							transition								
							zone villages								
Prevalence and	Kerneis et	Serology	2009	2000	Guinea	977	Gueckedou	11 3	na	na	na	na	na	na	Slightly higher
	140	Scrology	2005	2000	Guillea	577	Gueekeubu,	11.5	na	Πά	na	iid	Πά	iid	
Risk Factors of	al						Lola, and	%							lgG in rural vs
Lassa							Yomou								urban; no
Seropositivity in							prefectures								association with
Inhabitants of the															any rat
Forest Region of															interaction
Guinea: A Cross-															behaviors
Sectional Study															
Influence of	Longet et al ⁴²	Serology	2023	2016	Guinea	702		11-	na	na	na	na	na	Y	No assn with sex,
Landscape				-				59.6							age only in
Patterns on				2017				%							coastal, yes
Exposure to Lassa															environmental
<u>Fever Virus,</u>															fragmentation
<u>Guinea</u>															
Lassa virus activity	Lukashevich	Serology	1993		Guinea	3100	3100	4-	na	na	na	na	na	Y	High prev in
in Guinea:	et al ⁴³						households,	55%							secondary forest
distribution of							27 villages;								areas and
<u>human antiviral</u>							split								savannah, lower
antibody defined							between								in mountains and

using enzyme-							four biome								coast, no age or
<u>linked</u>							regions								sex differences
<u>immunosorbent</u>															
assay with															
<u>recombinant</u>															
antigen_															
Lassa Fever in the	Fraser et al ⁴⁴	Serology	1974	1970	Sierra			6.0%	na	na	na	na	na	na	
Eastern Province				-	Leone										
<u>of Sierra Leone,</u>				1972											
<u>1970–1972 </u>															
Seroprevalence of	Grant et al ⁴⁶	Serology	2023	2015	Sierra	10642	Sierra	10.6-	na	na	na	na	na	Y	Poor housing
anti-Lassa Virus				-	Leone		Leone,	20.1							construction;
IgG antibodies in				2018			"endemic",	%							proximity to
three districts of							"emerging",								bushland,
Sierra Leone: A							and "non								forested areas,
cross-sectional,							endemic"								and refuse; male;
population-based							regions								work in transport,
<u>study</u>															healthcare,
															farming, and
															mining; reverse
															assn with age;
															several house
															quality factors
															. ,

<u>Serosurveillance</u>	O'Hearn et	Serology	2016	2007	Sierra	675	Serum	50.2	na	na	na	na	na	na	
of viral pathogens	al ⁴⁵			-	Leone		samples	%							
circulating in West				2014			submitted to								
<u>Africa</u>							Lassa Diag								
							Lab at								
							Kenema Gov								
							Hospital								
							позрітаї								
<u>A Prospective</u>	McCormick	Serology	1987		Sierra	5213	5213	8-	na	na	na	na	na	na	Age 20-50 lgG
Study of the	et al ²³				Leone		individuals,	52%							peaks, mining
Epidemiology and							15 village								village >
Ecology of Lassa															agricultural
<u>Fever</u>															village,
															'disheveled'
															homes, food left
															out, etc
Lassa Fovor	Aromu	Sumptomatic	2005	2002	Nigoria	50	Specialist	22	22	22	67%	n 2	22	n 2	
Lassa rever,	Aremu		2003	2003	Nigeria	50		IIa	11a	11a	0778	IIa	IIa	IIa	
Nigeria, 2003 and	Omilabu et	rate		-			Teaching								
<u>2004</u>	al ⁸⁸			2004			Hospital in								
							Irrua 31								
							febrile, 17								
							healthy								
							contacts, 12								

							healthy								
							hospital staff								
<u>A cluster of</u>	Dan-Nwafor	Symptomatic	2019	2018	Nigeria	28	17	na	na	na	67%				
nosocomial Lassa	et al ⁸⁹	rate					asymptomat								
fever cases in a							ic contacts,								
tertiary health							10								
facility in Nigeria:							symptomati								
Description and							c cases								
lessons learned,															
<u>2018</u>															
Immunological	Ojonugwa	Symptomatic	2021	2018	Nigeria	233	Ondo state,	44.6	8.6%	0%	na	na	na	na	
screening of Lassa	Shaibu et al ⁹⁰	rate		-			Owo and	%							
Virus among				2019			Ose LGA;								
Health workers							102 HCW,								
and Contact of							109 case								
patients of Lassa							contacts, 22								
fever in Ondo							recovered								
<u>State</u>							cases								

Table S2. Population-level covariates with a potential association with LF occurrence.

Covariate	Reference
Population (2020)	63
Monthly precipitation (12) – Reduced by PCA	91
Monthly mean temperature (12) – Reduced by PCA	91
Monthly NDVI (12) – Reduced by PCA	92
Elevation	93
Longitude	
Latitude	
Healthcare access and quality index (HAQ)	67
Percent urban population	94
Mean travel time to nearest urban center	66
Percent frontier land cover (e.g., forest edge)	95
Percent tropical habitat	68
Percent agricultural land	69
Fraction forest loss since 2000	70
Probability of Mastomys spp presence	25
Probability of LASV presence in Mastomys spp	25
Presence of improved housing	71

International Wealth Index	72
Occurrence of bushmeat hunting	73
Malaria parasite prevalence	96

Table S3. Variable importance in the Random Forest model at the 1st administrative level. Variable

importance calculated with median projected FOI as the response variable.

	Variable
Covariate	Importance
Longitude	8.1
Mean travel time to nearest urban center	5.9
Healthcare access and quality index (HAQ)	3.4
Latitude	2.3
Probability of LASV presence in Mastomys spp	2.3
Fraction forest loss since 2000	2.3
Probability of Mastomys spp presence	2.1
Temperature – first principal component	1.9
Temperature – second principal component	1.9
NDVI – second principal component	1.7
Occurrence of bushmeat hunting	1.5
Precipitation – first principal component	1.5
Elevation	1.5
NDVI – first principal component	1.5
Temperature – third principal component	1.4
Presence of improved housing	1.3
Precipitation – second principal component	1.2
Malaria prevalence	1.2

Percent frontier land cover	1.2
Precipitation – third principal component	1.1
Percent agricultural land	0.9
Percent tropical habitat	0.3

Table S4. Variable importance in the Boosted regression tree model at the 1st administrative level.

Variable importance calculated with median projected FOI as the response variable.

	Variable
Covariate	Importance
Longitude	43.7
Mean travel time to nearest urban center	31.2
Probability of LASV presence in <i>Mastomys spp</i>	19.9
Probability of Mastomys spp presence	11.0
Latitude	9.8
Temperature – second principal component	7.9
Fraction forest loss since 2000	7.9
Percent frontier land cover	7.0
Malaria prevalence	6.2
Presence of improved housing	6.1
Temperature – first principal component	6.1
Healthcare access and quality index (HAQ)	4.8
Elevation	4.8
Percent agricultural land	4.2
NDVI – second principal component	3.6
Temperature – third principal component	3.6
Precipitation – first principal component	3.5
Precipitation – second principal component	3.0

Occurrence of bushmeat hunting	1.9
Precipitation – third principal component	1.8
NDVI – first principal component	1.2
Percent tropical habitat	0.0

Table S5. Variable importance in the Random Forest model at the 2nd administrative level. Variable

importance calculated with median projected FOI as the response variable.

	Variable
Covariate	Importance
Longitude	91.3
Healthcare access and quality index (HAQ)	53.0
Precipitation – second principal component	20.6
Fraction forest loss since 2000	14.7
Mean travel time to nearest urban center	11.7
NDVI – first principal component	10.4
Probability of LASV presence in Mastomys spp	8.8
Occurrence of bushmeat hunting	8.0
Precipitation – third principal component	6.7
Malaria prevalence	5.9
Probability of Mastomys spp presence	5.5
Temperature – second principal component	5.2
Precipitation – first principal component	4.7
Temperature – third principal component	4.6
Presence of improved housing	3.9
NDVI – second principal component	3.7
Latitude	3.7
Elevation	3.7

Temperature – first principal component	3.6
Percent agricultural land	2.7
Percent frontier land cover	2.1
Percent tropical habitat	0.6

Table S6. Coefficient estimates and t-values for the linear model with interaction terms at the 2nd

administrative level with median projected FOI	as the response variable.
--	---------------------------

Covariate	Estimate	SE	T value	P-value
Longitude	-1.38	0.43	-3.21	0.0015
Fraction forest loss since 2000	0.23	0.07	3.07	0.0024
Percent tropical habitat	-0.12	0.05	-2.64	0.0088
Percent frontier land cover	-0.10	0.05	-2.23	0.0265
Latitude	-2.25	1.03	-2.19	0.0297
Presence of improved housing	-0.23	0.12	-1.91	0.0575
Temperature – second principal component	-0.50	0.26	-1.90	0.0588
Temperature – first principal component	0.39	0.23	1.73	0.0843
Mean travel time to nearest urban center	0.48	0.30	1.62	0.1057
(Intercept)	-1.85	1.20	-1.54	0.1242
Malaria prevalence	-0.18	0.13	-1.35	0.1780
Precipitation – second principal component	0.35	0.28	1.25	0.2116
Precipitation – first principal component	-0.44	0.38	-1.18	0.2410
Healthcare access and quality index (HAQ)	-0.03	0.04	-0.95	0.3441
Precipitation – third principal component	-0.59	0.92	-0.64	0.5198
Percent agricultural land	-0.03	0.05	-0.59	0.5573
Elevation	0.26	0.46	0.56	0.5773
Probability of LASV presence in <i>Mastomys</i>				
spp	-0.07	0.15	-0.43	0.6651

NDVI – second principal component	-0.10	0.25	-0.41	0.6852
Occurrence of bushmeat hunting	-0.02	0.06	-0.34	0.7368
Temperature – third principal component	-0.15	0.45	-0.33	0.7446
NDVI – first principal component	0.02	0.09	0.24	0.8125
Interaction terms				
NDVI PC1:NDVI PC2	-0.05	0.07	-0.76	0.4478
NDVI PC1:Precipitation PC1	0.06	0.09	0.60	0.5499
NDVI PC1:Precipitation PC2	0.01	0.06	0.24	0.8119
NDVI PC1:Precipitation PC3	0.31	0.26	1.18	0.2402
NDVI PC1:Temperature PC1	-0.11	0.09	-1.25	0.2117
NDVI PC1:Temperature PC2	-0.12	0.09	-1.33	0.1854
NDVI PC1:Temperature PC3	-0.12	0.22	-0.52	0.6034
NDVI PC1:Elevation	-0.28	0.18	-1.56	0.1202
NDVI PC1:Longitude	-0.30	0.15	-1.95	0.0518
NDVI PC1:Latitude	0.61	0.50	1.22	0.2243
NDVI PC1:Mastomys occurrence	-0.02	0.07	-0.35	0.7241
NDVI PC1:Mastomys infection	0.01	0.07	0.14	0.8875
NDVI PC1:Improved housing	0.00	0.04	-0.12	0.9043
NDVI PC1:Malaria prevalence	-0.20	0.08	-2.43	0.0159
NDVI PC2:Precipitation PC1	0.23	0.27	0.87	0.3847
NDVI PC2:Precipitation PC2	-0.07	0.17	-0.40	0.6913
NDVI PC2:Precipitation PC3	0.36	0.65	0.55	0.5825
NDVI PC2:Temperature PC1	-0.41	0.23	-1.79	0.0742

NDVI PC2:Temperature PC2	0.48	0.19	2.50	0.0130
NDVI PC2:Temperature PC3	-0.42	0.50	-0.84	0.4005
NDVI PC2:Elevation	0.18	0.55	0.32	0.7480
NDVI PC2:Longitude	0.51	0.39	1.30	0.1936
NDVI PC2:Latitude	2.44	1.16	2.10	0.0364
NDVI PC2:Mastomys occurrence	-0.27	0.19	-1.45	0.1470
NDVI PC2:Mastomys infection	-0.03	0.19	-0.13	0.8956
NDVI PC2:Improved housing	-0.08	0.11	-0.70	0.4837
NDVI PC2:Malaria prevalence	-0.42	0.18	-2.32	0.0209
Precipitation PC1:Precipitation PC2	-0.25	0.12	-2.07	0.0396
Precipitation PC1:Precipitation PC3	0.41	0.21	1.98	0.0494
Precipitation PC1:Temperature PC1	0.11	0.20	0.52	0.6063
Precipitation PC1:Temperature PC2	-0.03	0.20	-0.16	0.8705
Precipitation PC1:Temperature PC3	0.43	0.44	0.98	0.3292
Precipitation PC1:Elevation	0.08	0.37	0.21	0.8345
Precipitation PC1:Longitude	0.14	0.26	0.54	0.5897
Precipitation PC1:Latitude	0.06	0.56	0.11	0.9148
Precipitation PC1:Mastomys occurrence	-0.18	0.16	-1.14	0.2535
Precipitation PC1:Mastomys infection	0.00	0.14	-0.02	0.9870
Precipitation PC1:Improved housing	-0.06	0.11	-0.50	0.6195
Precipitation PC1:Malaria prevalence	0.16	0.15	1.10	0.2740
Precipitation PC2:Precipitation PC3	-0.11	0.21	-0.51	0.6074
Precipitation PC2:Temperature PC1	0.49	0.13	3.78	0.0002

Precipitation PC2:Temperature PC2	-0.45	0.14	-3.27	0.0012
Precipitation PC2:Temperature PC3	0.31	0.31	0.99	0.3212
Precipitation PC2:Elevation	0.18	0.25	0.72	0.4727
Precipitation PC2:Longitude	-0.60	0.25	-2.35	0.0197
Precipitation PC2:Latitude	-1.84	0.59	-3.10	0.0022
Precipitation PC2:Mastomys occurrence	0.06	0.12	0.54	0.5910
Precipitation PC2:Mastomys infection	0.08	0.10	0.75	0.4517
Precipitation PC2:Improved housing	0.02	0.07	0.26	0.7957
Precipitation PC2:Malaria prevalence	0.07	0.12	0.62	0.5341
Precipitation PC3:Temperature PC1	-0.36	0.47	-0.75	0.4512
Precipitation PC3:Temperature PC2	0.96	0.42	2.28	0.0236
Precipitation PC3:Temperature PC3	-1.21	1.25	-0.97	0.3325
Precipitation PC3:Elevation	1.70	0.98	1.73	0.0845
Precipitation PC3:Longitude	1.61	0.94	1.72	0.0865
Precipitation PC3:Latitude	3.31	2.13	1.55	0.1216
Precipitation PC3:Mastomys occurrence	0.48	0.40	1.18	0.2384
Precipitation PC3:Mastomys infection	0.43	0.31	1.37	0.1727
Precipitation PC3:Improved housing	0.28	0.25	1.14	0.2534
Precipitation PC3:Malaria prevalence	0.37	0.29	1.28	0.2015
Temperature PC1:Temperature PC2	0.14	0.07	1.84	0.0673
Temperature PC1:Temperature PC3	-0.12	0.35	-0.33	0.7454
Temperature PC1:Elevation	0.09	0.13	0.69	0.4906
Temperature PC1:Longitude	-0.37	0.24	-1.54	0.1253
Temperature PC1:Latitude	0.18	0.50	0.36	0.7155
-------------------------------------	-------	------	-------	--------
Temperature PC1:Mastomys occurrence	-0.17	0.15	-1.14	0.2564
Temperature PC1:Mastomys infection	0.12	0.13	0.91	0.3636
Temperature PC1:Improved housing	0.11	0.10	1.06	0.2924
Temperature PC1:Malaria prevalence	-0.17	0.16	-1.06	0.2886
Temperature PC2:Temperature PC3	0.65	0.33	1.94	0.0533
Temperature PC2:Elevation	0.15	0.20	0.76	0.4468
Temperature PC2:Longitude	-0.20	0.26	-0.78	0.4350
Temperature PC2:Latitude	-0.38	0.56	-0.67	0.5026
Temperature PC2:Mastomys occurrence	-0.29	0.13	-2.26	0.0248
Temperature PC2:Mastomys infection	-0.12	0.11	-1.04	0.2974
Temperature PC2:Improved housing	-0.23	0.08	-2.98	0.0032
Temperature PC2:Malaria prevalence	-0.12	0.14	-0.86	0.3883
Temperature PC3:Elevation	0.26	0.92	0.29	0.7756
Temperature PC3:Longitude	0.95	0.72	1.31	0.1921
Temperature PC3:Latitude	1.03	2.03	0.51	0.6124
Temperature PC3:Mastomys occurrence	-0.39	0.39	-1.01	0.3153
Temperature PC3:Mastomys infection	0.47	0.37	1.27	0.2045
Temperature PC3:Improved housing	0.41	0.33	1.24	0.2179
Temperature PC3:Malaria prevalence	-0.11	0.32	-0.35	0.7273
Elevation:Longitude	-0.67	0.57	-1.17	0.2447
Elevation:Latitude	1.52	1.29	1.18	0.2400
Elevation:Mastomys occurrence	-0.81	0.28	-2.94	0.0036

Elevation:Mastomys infection	-0.14	0.23	-0.59	0.5548
Elevation:Improved housing	-0.23	0.21	-1.09	0.2765
Elevation:Malaria prevalence	-0.79	0.38	-2.07	0.0392
Longitude:Latitude	-0.07	0.75	-0.09	0.9253
Longitude:Mastomys occurrence	-0.29	0.25	-1.16	0.2490
Longitude:Mastomys infection	-0.28	0.21	-1.34	0.1817
Longitude:Improved housing	-0.06	0.22	-0.25	0.8045
Longitude:Malaria prevalence	0.15	0.31	0.48	0.6320
Latitude:Mastomys occurrence	0.31	0.82	0.38	0.7020
Latitude:Mastomys infection	-0.33	0.59	-0.56	0.5734
Latitude:Improved housing	-0.66	0.55	-1.20	0.2298
Latitude:Malaria prevalence	0.51	0.77	0.65	0.5133
Mastomys occurrence:Mastomys infection	0.10	0.12	0.81	0.4173
Mastomys occurrence:Improved housing	0.05	0.07	0.77	0.4450
Mastomys occurrence:Malaria prevalence	0.01	0.12	0.07	0.9457
Mastomys infection:Improved housing	0.12	0.07	1.64	0.1015
Mastomys infection:Malaria prevalence	0.22	0.12	1.83	0.0677
Improved housing:Malaria prevalence	-0.01	0.08	-0.08	0.9325

 Table S7. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 1st administrative level when the seroreversion rate is

 0%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in

 seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

		Annual Lassa Fever incidence rate (per 1,000)									
		Ser	oreverted – No Immı	unity	Seroreverted – Partial Immunity						
		Seropos. – Full	Seropos. – Part.	Seropos. – Part.	Seropos. – Full	Seropos. – Part.	Seropos. – Part.				
Country	Admin1	Immunity	Immunity (Hi)	Immunity (Lo)	Immunity	Immunity (Hi)	Immunity (Lo)				
Nigeria	Ondo	3.9 (3.3 - 4.4)	5.0 (4.1-6.1)	5.6 (4.5 - 6.9)	3.9 (3.3 - 4.4)	5.0 (4.1-6.1)	5.6 (4.5 – 6.9)				
Mali	Sikasso	3.1 (2.7 – 3.4)	3.6 (3.1 - 4.1)	3.9 (3.3 - 4.4)	3.1 (2.7 - 3.4)	3.6 (3.1 - 4.1)	3.9 (3.3 - 4.4)				
Sierra											
Leone	Southern	2.7 (2.2 - 3.1)	3.2 (2.5 – 3.9)	3.4 (2.7 – 4.2)	2.7 (2.2 - 3.1)	3.2 (2.5 – 3.9)	3.4 (2.7 – 4.2)				
Guinea	Faranah	2.3 (2.2 – 2.5)	2.7 (2.4 - 2.9)	2.8 (2.6 - 3.1)	2.3 (2.2 - 2.5)	2.7 (2.4 – 2.9)	2.8 (2.6 - 3.1)				
Cote											
d'Ivoire	Lacs	2.2 (1.7 – 2.8)	2.5 (1.9 - 3.3)	2.6 (2.0 – 3.5)	2.2 (1.7 – 2.8)	2.5 (1.9 - 3.3)	2.6 (2.0 - 3.6)				
Liberia	Grand Bassa	2.1 (0.4 - 6.5)	2.4 (0.4 - 49.7)	2.5 (0.4 - 70.8)	2.1 (0.4 - 6.5)	2.4 (0.4 - 49.7)	2.5 (0.4 - 70.8)				
Guinea	Nzerekore	1.8 (1.7 – 1.8)	1.9 (1.8 - 2.0)	2.0 (1.9 - 2.1)	1.8 (1.7 – 1.8)	1.9 (1.8 – 2.0)	2.0 (1.9 - 2.1)				

Liberia	Bong	1.7 (0.3 – 6.5)	1.9 (0.3 – 47.5)	2.0 (0.3 - 67.8)	1.7 (0.3 – 6.5)	1.9 (0.3 – 47.7)	2.0 (0.3 - 67.6)
Sierra							
Leone	Eastern	1.7 (1.6 – 1.7)	1.8 (1.7 – 1.9)	1.9 (1.8 – 2.0)	1.7 (1.6 – 1.8)	1.8 (1.7 – 1.9)	1.9 (1.8 – 2.0)
Nigeria	Ebonyi	1.2 (0.2 - 6.9)	1.3 (0.2 - 21.6)	1.3 (0.2 – 28.7)	1.2 (0.2 - 6.8)	1.3 (0.2 - 21.6)	1.3 (0.2 – 28.8)
Nigeria	Taraba	1.1 (0.1 – 7.0)	1.2 (0.1 - 24.8)	1.2 (0.1 – 33.5)	1.1 (0.1 – 7.0)	1.2 (0.1 – 24.8)	1.2 (0.1 – 33.5)
Nigeria	Edo	1.1 (0.9 – 1.3)	1.1 (1.0 – 1.3)	1.2 (1.0 – 1.4)	1.1 (0.9 – 1.3)	1.1 (1.0 – 1.3)	1.2 (1.0 – 1.4)
Benin	Borgou	1.1 (0.2 - 6.1)	1.1 (0.2 - 22.8)	1.1 (0.2 - 31.0)	1.1 (0.2 - 6.0)	1.1 (0.2 – 22.8)	1.1 (0.2 - 31.1)
Sierra							
Leone	Northern	1.0 (0.9 - 1.0)	1.0 (0.9 – 1.1)	1.0 (1.0 – 1.1)	1.0 (0.9 – 1.0)	1.0 (0.9 – 1.1)	1.0 (1.0 – 1.1)
Liberia	Nimba	1.0 (0.1-6.2)	1.0 (0.1 – 25.0)	1.0 (0.1 - 34.2)	1.0 (0.1-6.1)	1.0 (0.1 – 25.2)	1.0 (0.1 - 34.3)
Sierra							
Leone	Western	1.0 (0.6 – 1.5)	1.0 (0.6 – 1.6)	1.0 (0.6 – 1.6)	1.0 (0.6 – 1.5)	1.0 (0.6 – 1.6)	1.0 (0.6 – 1.6)
Guinea	Kankan	0.9 (0.7 – 1.2)	1.0 (0.7 – 1.3)	1.0 (0.8 – 1.3)	1.0 (0.7 – 1.2)	1.0 (0.7 – 1.3)	1.0 (0.8 – 1.3)
Guinea	Kindia	0.9 (0.8 - 1.1)	1.0 (0.9 - 1.1)	1.0 (0.9 – 1.2)	0.9 (0.8 - 1.1)	1.0 (0.9 – 1.1)	1.0 (0.9 – 1.2)
Ghana	Ashanti	0.9 (0.4 - 1.7)	1.0 (0.4 - 1.9)	1.0 (0.4 - 2.0)	0.9 (0.4 - 1.7)	1.0 (0.4 - 1.9)	1.0 (0.4 - 2.0)
Ghana	Eastern	0.8 (0.4 – 1.3)	0.9 (0.5 – 1.5)	0.9 (0.5 - 1.5)	0.8 (0.4 - 1.3)	0.9 (0.5 - 1.5)	0.9 (0.5 - 1.5)

 Table S8. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 2nd administrative level when the seroreversion rate is

 0%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in

 seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

				Annual Lassa Fever incidence rate (per 1,000)						
			Ser	oreverted – No Imm	unity	Seroreverted – Partial Immunity				
			Seropos. – Full	Seropos. – Part.	Seropos. – Part.	Seropos. – Full	Seropos. – Part.	Seropos. – Part.		
Country	Admin1	Admin2	Immunity	Immunity (Hi)	Immunity (Lo)	Immunity	Immunity (Hi)	Immunity (Lo)		
Sierra										
Leone	Southern	Moyamba	4.7 (4.0 – 5.2)	7.5 (5.6 – 9.7)	8.8 (6.3 – 11.8)	4.7 (4.1 – 5.2)	7.5 (5.6 – 9.6)	8.8 (6.3 – 11.9)		
Nigeria	Ondo	Ose	4.6 (3.9 – 5.2)	6.6 (5.1 – 8.3)	7.6 (5.6 – 9.7)	4.6 (3.9 – 5.1)	6.6 (5.1 - 8.2)	7.6 (5.7 – 9.8)		
Sierra										
Leone	Northern	Bombali	3.7 (2.5 – 4.8)	4.9 (2.9 – 7.6)	5.5 (3.0 – 9.1)	3.7 (2.5 – 4.8)	4.9 (2.9 – 7.6)	5.5 (3.1 - 9.0)		
Sierra										
Leone	Eastern	Kono	3.4 (0.2 - 5.7)	4.3 (0.2 - 13.4)	4.7 (0.2 – 17.1)	3.4 (0.2 - 5.7)	4.3 (0.2 - 13.3)	4.7 (0.2 – 17.1)		
Sierra										
Leone	Northern	Koinadugu	3.4 (1.4 - 4.9)	4.3 (1.5 - 8.2)	4.7 (1.5 – 9.7)	3.4 (1.4 - 4.9)	4.2 (1.5 - 8.1)	4.6 (1.5 - 9.7)		

77

Nigeria	Edo	Esan West	3.3 (2.8 – 3.7)	4.1 (3.3 – 4.8)	4.4 (3.6 – 5.3)	3.3 (2.8 – 3.8)	4.0 (3.3 - 4.8)	4.4 (3.6 – 5.3)
Liberia	Bong	Suakoko	3.3 (0.9 - 6.5)	4.1 (0.9 - 49.8)	4.6 (1.0 –70.9)	3.3 (0.9 - 6.5)	4.2 (1.0 - 49.8)	4.6 (1.0 – 70.9)
Guinea	Nzerekore	Macenta	3.2 (3.0 – 3.5)	4.0 (3.6 – 4.4)	4.4 (3.9 – 4.9)	3.2 (3.0 – 3.5)	4.0 (3.6 - 4.4)	4.4 (3.9 - 4.9)
Sierra								
Leone	Southern	Pujehun	3.1 (1.1 - 4.9)	3.8 (1.2 - 8.1)	4.2 (1.2 – 9.7)	3.2 (1.1 - 4.9)	3.8 (1.2 - 8.1)	4.2 (1.2 – 9.7)
Mali	Sikasso	Bougouni	3.1 (2.7 – 3.4)	3.6 (3.1 - 4.1)	3.8 (3.3 - 4.4)	3.1 (2.7 – 3.4)	3.6 (3.1 - 4.1)	3.8 (3.3 - 4.4)
Sierra		Western						
Leone	Western	Rural	2.4 (0.1 - 5.2)	2.8 (0.1-9.5)	2.9 (0.1 – 11.6)	2.4 (0.1 - 5.2)	2.8 (0.1 - 9.5)	2.9 (0.1 - 11.6)
	Grand							
Liberia	Bassa	District #3	2.4 (0.5 - 6.4)	2.7 (0.6 – 44.6)	2.9 (0.6 - 63.0)	2.4 (0.5 - 6.4)	2.7 (0.6 - 44.6)	2.9 (0.6 - 62.8)
Guinea	Faranah	Faranah	2.4 (2.2 – 2.5)	2.7 (2.4 – 2.9)	2.8 (2.6 - 3.1)	2.4 (2.1 - 2.5)	2.7 (2.4 – 2.9)	2.8 (2.6 - 3.1)
Cote								
d'Ivoire	Montagnes	Cavally	2.3 (1.7 – 2.9)	2.7 (1.9 – 3.5)	2.8 (2.0 - 3.8)	2.3 (1.7 – 2.9)	2.7 (1.9 – 3.5)	2.8 (2.0 - 3.8)
Nigeria	Ondo	Owo	2.3 (1.4 - 3.2)	2.6 (1.5 – 3.9)	2.7 (1.5 – 4.2)	2.3 (1.4 - 3.2)	2.6 (1.5 - 3.9)	2.7 (1.5 – 4.2)
Sierra								
Leone	Eastern	Kailahun	2.3 (1.5 - 3.1)	2.6 (1.6 – 3.7)	2.7 (1.6 - 4.0)	2.3 (1.5 - 3.1)	2.5 (1.6 - 3.7)	2.7 (1.6 - 4.0)
Guinea	Kindia	Kindia	2.1 (1.7 – 2.6)	2.4 (1.9 - 2.9)	2.5 (2.0 - 3.2)	2.1 (1.7 – 2.5)	2.4 (1.9 - 2.9)	2.5 (2.0 - 3.1)

Guinea	Nzerekore	Gueckedou	1.9 (1.8 – 2.1)	2.1 (2.0 – 2.3)	2.2 (2.0 – 2.4)	1.9 (1.8 – 2.1)	2.1 (2.0 - 2.3)	2.2 (2.0 - 2.4)
Guinea	Nzerekore	Lola	1.9 (1.7 – 2.2)	2.1 (1.8 – 2.5)	2.2 (1.9 – 2.6)	1.9 (1.6 – 2.2)	2.1 (1.8 - 2.4)	2.2 (1.9 - 2.6)
Cote								
d'Ivoire	Montagnes	Guemon	1.9 (0.9 – 3.0)	2.1 (0.9 – 3.7)	2.2 (1.0 – 3.9)	1.9 (0.9 – 3.0)	2.1 (0.9-3.6)	2.2 (1.0 - 3.9)

 Table S9. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 1st administrative level when the seroreversion rate is

 3%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in

 seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

		Annual Lassa Fever incidence rate (per 1,000)								
		Ser	oreverted – No Immu	unity	Seroreverted – Partial Immunity					
		Seropos. – Full	Seropos. – Part.	Seropos. – Part.	Seropos. – Full	Seropos. – Part.	Seropos. – Part.			
Country	Admin1	Immunity	Immunity (Hi)	Immunity (Lo)	Immunity	Immunity (Hi)	Immunity (Lo)			
Nigeria	Ondo	6.7 (5.6 – 7.5)	8.8 (7.0 – 10.8)	9.9 (7.6 – 12.3)	5.9 (5.1-6.6)	8.0 (6.4 - 9.8)	9.1 (7.1 – 11.3)			
Mali	Sikasso	5.0 (4.5 – 5.6)	5.9 (5.1 - 6.8)	6.4 (5.5 - 7.4)	4.6 (4.2 - 5.1)	5.5 (4.8 - 6.3)	6.0 (5.2 - 6.9)			
Sierra										
Leone	Southern	4.3 (3.6 - 5.1)	5.0 (4.0 - 6.2)	5.3 (4.2 - 6.8)	3.9 (3.3 - 4.6)	4.6 (3.8 – 5.7)	5.0 (4.0 - 6.2)			
Guinea	Faranah	4.3 (4.0 – 4.6)	5.0 (4.5 – 5.4)	5.3 (4.8 - 5.8)	3.9 (3.7 – 4.2)	4.6 (4.2 - 5.0)	4.9 (4.5 - 5.4)			
Cote										
d'Ivoire	Lacs	3.6 (2.8 - 4.5)	4.1 (3.0 - 5.2)	4.3 (3.1-5.6)	3.3 (2.6 - 4.1)	3.8 (2.9 - 4.9)	4.0 (3.0 – 5.3)			
Guinea	Nzerekore	3.0 (2.9 - 3.1)	3.3 (3.1 - 3.5)	3.4 (3.3 - 3.6)	2.8 (2.7 – 2.9)	3.1 (3.0 - 3.3)	3.3 (3.1 - 3.4)			

Sierra							
Leone	Eastern	2.8 (2.6 – 2.9)	3.0 (2.8 – 3.2)	3.1 (2.9 – 3.3)	2.6 (2.5 – 2.7)	2.9 (2.7 – 3.0)	3.0 (2.8 – 3.1)
Liberia	Grand Bassa	2.4 (0.3 - 6.9)	2.6 (0.3 - 9.6)	2.7 (0.3 - 11.0)	2.3 (0.4 - 6.0)	2.5 (0.4 - 8.7)	2.6 (0.3 - 10.0)
Liberia	Bong	1.9 (0.3 - 6.8)	2.0 (0.3 – 9.6)	2.0 (0.3 - 10.9)	1.8 (0.3 - 6.0)	1.9 (0.3 - 8.7)	2.0 (0.3 - 10.0)
Nigeria	Edo	1.8 (1.6 – 2.1)	1.9 (1.6 – 2.2)	2.0 (1.7 – 2.3)	1.8 (1.5 – 2.0)	1.9 (1.6 - 2.2)	1.9 (1.6 – 2.2)
Ghana	Ashanti	1.7 (0.7 – 3.1)	1.8 (0.7 – 3.4)	1.8 (0.7 – 3.6)	1.6 (0.7 – 2.9)	1.7 (0.7 – 3.2)	1.8 (0.7 – 3.4)
Sierra							
Leone	Western	1.6 (1.0 – 2.5)	1.7 (1.0 – 2.7)	1.7 (1.0 – 2.8)	1.6 (0.9-2.4)	1.6 (1.0 – 2.6)	1.7 (1.0 – 2.7)
Guinea	Kindia	1.6 (1.4 – 1.8)	1.7 (1.5 – 1.9)	1.7 (1.5 – 1.9)	1.5 (1.4 – 1.8)	1.6 (1.4 - 1.8)	1.7 (1.4 – 1.9)
Sierra							
Leone	Northern	1.6 (1.5 – 1.7)	1.6 (1.5 – 1.8)	1.7 (1.6 – 1.8)	1.5 (1.4 – 1.6)	1.6 (1.5 – 1.7)	1.6 (1.5 – 1.8)
Guinea	Kankan	1.5 (1.2 – 2.0)	1.6 (1.2 – 2.1)	1.6 (1.2 – 2.1)	1.5 (1.2 – 1.9)	1.6 (1.2 - 2.0)	1.6 (1.2 – 2.0)
Ghana	Eastern	1.5 (0.7 – 2.4)	1.6 (0.7 – 2.6)	1.6 (0.7 – 2.7)	1.5 (0.7 – 2.3)	1.5 (0.7 – 2.5)	1.6 (0.7 – 2.6)
Nigeria	Ebonyi	1.4 (0.2 – 7.4)	1.4 (0.2 – 10.3)	1.5 (0.2 – 11.8)	1.4 (0.2 - 6.4)	1.4 (0.2 - 9.4)	1.4 (0.2 – 10.8)
Liberia	Nimba	1.2 (0.1-6.4)	1.2 (0.1 - 8.6)	1.3 (0.1-9.7)	1.2 (0.1 – 5.6)	1.2 (0.1 - 7.8)	1.2 (0.1 - 8.8)
Nigeria	Borno	1.1 (0.7 – 1.6)	1.1 (0.7 – 1.7)	1.2 (0.7 – 1.7)	1.1 (0.7 – 1.6)	1.1 (0.7 – 1.6)	1.1 (0.7 – 1.7)
Benin	Borgou	1.1 (0.2 – 6.3)	1.1 (0.2 - 8.4)	1.2 (0.2 - 9.5)	1.1 (0.2 – 5.5)	1.1 (0.2 – 7.7)	1.1 (0.2 - 8.7)

 Table S10. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 2nd administrative level when the seroreversion rate is

 3%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in

 seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

			Annual Lassa Fever incidence rate (per 1,000)						
			Se	roreverted – No Imm	unity	Sero	nmunity		
			Seropos. – Full	Seropos. – Part.	Seropos. – Part.	Seropos. – Full	Seropos. – Part.	Seropos. – Part.	
Country	Admin1	Admin2	Immunity	Immunity (Hi)	Immunity (Lo)	Immunity	Immunity (Hi)	Immunity (Lo)	
Nigeria	Ondo	Ose	8.3 (6.8 - 9.5)	12.9 (9.2 - 17.1)	15.0 (10.2 - 20.8)	7.2 (6.1 - 8.0)	11.7 (8.4 - 15.7)	13.9 (9.5 – 19.5)	
Sierra									
Leone	Southern	Moyamba	7.9 (6.7 – 8.9)	12.4 (9.2 - 16.4)	14.6 (10.4 – 19.9)	6.8 (5.9 – 7.4)	11.3 (8.3 – 14.8)	13.4 (9.6 – 18.4)	
Nigeria	Edo	Esan West	6.4 (5.4 - 7.4)	8.4 (6.6 - 10.3)	9.3 (7.2 - 11.8)	5.7 (4.9 –6.4)	7.6 (6.1 - 9.4)	8.6 (6.7 – 10.9)	
Sierra									
Leone	Northern	Bombali	6.4 (4.0 - 8.3)	8.6 (4.6 - 13.7)	9.6 (4.8 - 16.3)	5.6 (3.7 –7.0)	7.8 (4.3 – 12.5)	8.9 (4.5 – 15.0)	
Sierra									
Leone	Northern	Koinadugu	6.0 (2.1 - 8.8)	7.6 (2.2 – 15.8)	8.5 (2.3 – 19.2)	5.3 (2.0 -7.4)	7.0 (2.2 – 14.4)	7.9 (2.2 – 17.9)	
Guinea	Nzerekore	Macenta	5.9 (5.4 - 6.4)	7.6 (6.7 – 8.4)	8.4 (7.3 – 9.5)	5.2 (4.8 - 5.6)	6.9 (6.2 - 7.7)	7.7 (6.8 – 8.7)	

Mali	Sikasso	Bougouni	5.0 (4.5 – 5.6)	6.0 (5.2 – 6.8)	6.4 (5.5 – 7.4)	4.7 (4.2 – 5.1)	5.6 (4.9 – 6.3)	6.0 (5.2 – 6.9)
Sierra								
Leone	Southern	Pujehun	4.7 (1.6 – 7.7)	5.6 (1.6 – 11.9)	6.0 (1.7 – 13.8)	4.3 (1.5 – 6.6)	5.1 (1.6 – 10.8)	5.6 (1.7 – 12.8)
Guinea	Faranah	Faranah	4.3 (3.9 – 4.6)	5.0 (4.5 – 5.4)	5.3 (4.8 – 5.8)	3.9 (3.6 - 4.2)	4.6 (4.2 - 5.0)	5.0 (4.5 - 5.4)
Sierra								
Leone	Eastern	Kono	4.2 (0.2 – 9.2)	4.9 (0.2 – 18.2)	5.2 (0.2 – 22.5)	3.9 (0.2 – 7.7)	4.6 (0.2 – 16.7)	4.9 (0.2 – 21.0)
Nigeria	Ondo	Owo	3.9 (2.4 – 5.4)	4.4 (2.6 - 6.6)	4.7 (2.6 – 7.2)	3.6 (2.3 - 4.9)	4.1 (2.5 – 6.2)	4.4 (2.6 - 6.7)
Sierra								
Leone	Eastern	Kailahun	3.8 (2.4 – 5.2)	4.4 (2.6 - 6.4)	4.6 (2.7 – 7.0)	3.5 (2.3 – 4.7)	4.1 (2.5 – 5.9)	4.3 (2.5 – 6.5)
Cote								
d'Ivoire	Montagnes	Cavally	3.8 (2.8 – 4.9)	4.3 (3.0 – 5.8)	4.5 (3.1 - 6.3)	3.5 (2.6 - 4.4)	4.0 (2.9 – 5.4)	4.3 (3.0 – 5.8)
Guinea	Kindia	Kindia	3.5 (2.9 – 4.2)	3.9 (3.1 – 4.8)	4.1 (3.3 – 5.1)	3.2 (2.7 – 3.8)	3.7 (3.0 – 4.5)	3.9 (3.1 - 4.8)
Sierra		Western						
Leone	Western	Rural	3.5 (0.1 - 8.5)	3.9 (0.1 – 14.7)	4.1 (0.1 – 17.6)	3.2 (0.1 – 7.2)	3.6 (0.1 – 13.3)	3.9 (0.1 – 16.3)
Liberia	Bong	Suakoko	3.4 (0.9 – 7.2)	3.8 (0.9 – 10.4)	4.0 (0.9 - 12.0)	3.2 (0.9 - 6.2)	3.6 (0.9 – 9.5)	3.8 (0.9 - 11.0)
Guinea	Nzerekore	Gueckedou	3.2 (3.0 – 3.5)	3.6 (3.3 – 3.9)	3.8 (3.4 - 4.1)	3.0 (2.8 - 3.3)	3.4 (3.1 - 3.7)	3.6 (3.3 – 3.9)
Guinea	Nzerekore	Lola	3.1 (2.7 – 3.5)	3.5 (2.9 – 4.0)	3.6 (3.0 – 4.2)	2.9 (2.5 – 3.3)	3.3 (2.8 – 3.8)	3.4 (2.9 - 4.0)

Cote								
d'Ivoire	Montagnes	Guemon	3.1 (1.5 – 4.9)	3.4 (1.5 – 5.9)	3.5 (1.6 – 6.3)	2.9 (1.4 - 4.4)	3.2 (1.5 – 5.4)	3.4 (1.5 – 5.9)
Guinea	Nzerekore	Yamou	2.9 (2.6 - 3.2)	3.2 (2.8 – 3.6)	3.3 (2.9 – 3.7)	2.7 (2.4 – 3.0)	3.0 (2.6 – 3.4)	3.1 (2.8 – 3.5)



Figure S1. Maps of FOI projections from LF case/death data and reporting probabilities at the (A) 1^{st} and (B) 2^{nd} administrative levels with seroreversion = 0%.



Figure S2. Maps of FOI projections from LF case/death data and reporting probabilities at the (A) 1^{st} and (B) 2^{nd} administrative levels with seroreversion = 3%.



Figure S3. Scatterplots showing the relationship between the statistical regression predictions of FOI on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities for each of the eight statistical models (plus a null intercept-only model) included in our analysis. Plots are restricted to FOI estimates that were used in model fitting and do not include data held out for model validation. Results are for the 2nd administrative level and a 6% seroreversion rate.



Figure S4. Scatterplots showing the relationship between the statistical regression predictions of FOI on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities for each of the eight statistical models (plus a null intercept-only model) included in our analysis. Plots are restricted to FOI estimates that were used in model fitting and do not include data held out for model validation. Results are for the 2nd administrative level and a 6% seroreversion rate.



Figure S5. Scatterplots showing the cross-validation performance of each statistical regression model. Regression predictions of FOI for withheld data are on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities on the y-axis. Results are for the 1st administrative level and a 6% seroreversion rate.



Figure S6. Scatterplots showing the cross-validation performance of each statistical regression model. Regression predictions of FOI for withheld data are on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities on the y-axis. Results are for the 2nd administrative level and a 6% seroreversion rate.



Figure S7. Map of ensemble model-based FOI estimates at the (A) 1^{st} and (B) 2^{nd} administrative levels with seroreversion = 0%.



Figure S8. Map of ensemble model-based FOI estimates at the (A) 1^{st} and (B) 2^{nd} administrative levels with seroreversion = 3%.



Figure S9. Map of ensemble model-based FOI estimates at the (A) 1^{st} and (B) 2^{nd} administrative levels with seroreversion = 6%.

References

- Garry RF. Lassa fever the road ahead. *Nat Rev Microbiol*. 2023;21(2):87-96. doi:10.1038/s41579-022-00789-8
- 2. WHO. Lassa fever. Accessed January 30, 2024. https://www.who.int/health-topics/lassa-fever
- McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A Prospective Study of the Epidemiology and Ecology of Lassa Fever. *The Journal of Infectious Diseases*. 1987;155(3):437-444. doi:10.1093/infdis/155.3.437
- US CDC. Lassa Fever | CDC. April 26, 2022. Accessed January 30, 2024. https://www.cdc.gov/vhf/lassa/index.html
- Redding DW, Gibb R, Dan-Nwafor CC, et al. Geographical drivers and climate-linked dynamics of Lassa fever in Nigeria. *Nat Commun*. 2021;12(1):5759. doi:10.1038/s41467-021-25910-y
- LaVergne SM, Sakabe S, Momoh M, et al. Expansion of CD8+ T cell population in Lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors. *PLOS Neglected Tropical Diseases*. 2022;16(11):e0010882. doi:10.1371/journal.pntd.0010882
- Safronetz D, Sogoba N, Diawara SI, et al. Annual Incidence of Lassa Virus Infection in Southern Mali. Am J Trop Med Hyg. 2017;96(4):944-946. doi:10.4269/ajtmh.16-0821
- Shaffer JG, Schieffelin JS, Momoh M, et al. Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012–2019. *Microorganisms*. 2021;9(3):586. doi:10.3390/microorganisms9030586
- Shaffer JG, Schieffelin JS, Gbakie M, et al. A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges. *PLOS ONE*. 2019;14(3):e0214284. doi:10.1371/journal.pone.0214284

- Sigfrid L, Moore C, Salam AP, et al. A rapid research needs appraisal methodology to identify evidence gaps to inform clinical research priorities in response to outbreaks—results from the Lassa fever pilot. *BMC Medicine*. 2019;17(1):107. doi:10.1186/s12916-019-1338-1
- Siddle KJ, Eromon P, Barnes KG, et al. Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. *New England Journal of Medicine*. 2018;379(18):1745-1753. doi:10.1056/NEJMoa1804498
- Dalhat MM, Olayinka A, Meremikwu MM, et al. Epidemiological trends of Lassa fever in Nigeria, 2018–2021. PLOS ONE. 2022;17(12):e0279467. doi:10.1371/journal.pone.0279467
- Koch MR, Kanneh L, Wise PH, et al. Health seeking behavior after the 2013–16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone. *PLOS Neglected Tropical Diseases*. 2021;15(7):e0009576. doi:10.1371/journal.pntd.0009576
- 14. Penfold S, Adegnika AA, Asogun D, et al. A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)–Study protocol. *PLoS One*. 2023;18(3):e0283643.
 doi:10.1371/journal.pone.0283643
- Goios A, Varma A, Kagia C, Otiende M, Suykerbuyk P. Enable Lassa Research Programme Mid-term Workshop. Published online 2022. Accessed August 12, 2024. https://media.tghn.org/medialibrary/2023/03/CEPI_Enable_2022_Abuja_Report_Final.pdf
- 16. Lecompte E, Fichet-Calvet E, Daffis S, et al. Mastomys natalensis and Lassa Fever, West Africa. *Emerging Infectious Diseases*. 2006;12(12):1971-1974. doi:10.3201/eid1212.060812

- Fichet-Calvet E, Lecompte E, Koivogui L, et al. Fluctuation of abundance and Lassa virus prevalence in Mastomys natalensis in Guinea, West Africa. *Vector-Borne and Zoonotic Diseases*. 2007;7(2):119-128.
- Fichet-Calvet E, Becker-Ziaja B, Koivogui L, Günther S. Lassa Serology in Natural Populations of Rodents and Horizontal Transmission. *Vector Borne Zoonotic Dis*. 2014;14(9):665-674. doi:10.1089/vbz.2013.1484
- Clark J, Yakob L, Douno M, et al. Domestic risk factors for increased rodent abundance in a Lassa fever endemic region of rural Upper Guinea. *Sci Rep.* 2021;11(1):20698. doi:10.1038/s41598-021-00113-z
- Safronetz D, Sogoba N, Lopez JE, et al. Geographic Distribution and Genetic Characterization of Lassa Virus in Sub-Saharan Mali. *PLOS Neglected Tropical Diseases*. 2013;7(12):e2582. doi:10.1371/journal.pntd.0002582
- 21. Mariën J, Lo Iacono G, Rieger T, Magassouba N, Günther S, Fichet-Calvet E. Households as hotspots of Lassa fever? Assessing the spatial distribution of Lassa virus-infected rodents in rural villages of Guinea. *Emerg Microbes Infect*. 2020;9(1):1055-1064. doi:10.1080/22221751.2020.1766381
- 22. Happi AN, Olumade TJ, Ogunsanya OA, et al. Increased Prevalence of Lassa Fever Virus-Positive Rodents and Diversity of Infected Species Found during Human Lassa Fever Epidemics in Nigeria. *Microbiology Spectrum*. 2022;10(4):e00366-22. doi:10.1128/spectrum.00366-22
- McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A Prospective Study of the Epidemiology and Ecology of Lassa Fever. *The Journal of Infectious Diseases*. 1987;155(3):437-444. doi:10.1093/infdis/155.3.437

- 24. Safronetz D, Sogoba N, Diawara SI, et al. Annual Incidence of Lassa Virus Infection in Southern Mali. *Am J Trop Med Hyg*. 2017;96(4):944-946. doi:10.4269/ajtmh.16-0821
- Basinski AJ, Fichet-Calvet E, Sjodin AR, et al. Bridging the gap: Using reservoir ecology and human serosurveys to estimate Lassa virus spillover in West Africa. *PLOS Computational Biology*. 2021;17(3):e1008811. doi:10.1371/journal.pcbi.1008811
- Peterson AT, Moses LM, Bausch DG. Mapping Transmission Risk of Lassa Fever in West Africa: The Importance of Quality Control, Sampling Bias, and Error Weighting. *PLOS ONE*. 2014;9(8):e100711. doi:10.1371/journal.pone.0100711
- 27. Fichet-Calvet. Risk Maps of Lassa Fever in West Africa. *PLOS Neglected Tropical Diseases*. 2009;3(3):e388. doi:10.1371/journal.pntd.0000388
- Redding DW, Moses LM, Cunningham AA, Wood J, Jones KE. Environmental-mechanistic modelling of the impact of global change on human zoonotic disease emergence: a case study of Lassa fever. *Methods in Ecology and Evolution*. 2016;7(6):646-655. doi:10.1111/2041-210X.12549
- Safronetz D, Sogoba N, Lopez JE, et al. Geographic Distribution and Genetic Characterization of Lassa Virus in Sub-Saharan Mali. *PLOS Neglected Tropical Diseases*. 2013;7(12):e2582. doi:10.1371/journal.pntd.0002582
- 30. Lassa fever. WHO. Accessed April 27, 2023. https://www.who.int/health-topics/lassa-fever

 Akhmetzhanov AR, Asai Y, Nishiura H. Quantifying the seasonal drivers of transmission for Lassa fever in Nigeria. *Philos Trans R Soc Lond B Biol Sci.* 2019;374(1775):20180268. doi:10.1098/rstb.2018.0268

32. Lassa Fever | CDC. April 26, 2022. Accessed May 4, 2023. https://www.cdc.gov/vhf/lassa/index.html

97

33. Priority diseases. CEPI. Accessed May 4, 2023. https://cepi.net/research_dev/priority-diseases/

- 34. Hallam HJ, Hallam S, Rodriguez SE, et al. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. *npj Vaccines*. 2018;3(1):1-12. doi:10.1038/s41541-018-0049-5
- Ramanathan R, Stibitz S, Pratt D, Roberts J. Use of controlled human infection models (CHIMs) to support vaccine development: US regulatory considerations. *Vaccine*. 2019;37(31):4256-4261. doi:10.1016/j.vaccine.2019.06.009
- Disease outbreak Lassa fever Nigeria 1 March 2018. WHO | Regional Office for Africa. March 24, 2023. Accessed March 27, 2023. https://www.afro.who.int/health-topics/lassa-fever/outbreak/1-march-2018-nigeria
- Saleh F, Popoola BO, Arinze C, et al. Adapting public health response through lessons learnt: Nigeria's experience from Lassa fever and COVID-19. *BMJ Global Health*. 2022;7(Suppl 7):e007993. doi:10.1136/bmjgh-2021-007993
- Garry RF. Lassa fever the road ahead. *Nat Rev Microbiol*. 2023;21(2):87-96. doi:10.1038/s41579-022-00789-8
- 39. Siddle KJ, Eromon P, Barnes KG, et al. Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. *N Engl J Med*. 2018;379(18):1745-1753. doi:10.1056/NEJMoa1804498
- 40. Kernéis S, Koivogui L, Magassouba N, et al. Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest Region of Guinea: A Cross-Sectional Study. *PLOS Neglected Tropical Diseases*. 2009;3(11):e548. doi:10.1371/journal.pntd.0000548

- Klempa B, Koulemou K, Auste B, et al. Seroepidemiological study reveals regional co-occurrence of Lassa- and Hantavirus antibodies in Upper Guinea, West Africa. *Tropical Medicine & International Health*. 2013;18(3):366-371. doi:10.1111/tmi.12045
- 42. Longet S, Leggio C, Bore JA, et al. Influence of Landscape Patterns on Exposure to Lassa Fever Virus, Guinea. *Emerg Infect Dis*. 2023;29(2):304-313. doi:10.3201/eid2902.212525
- Lukashevich IS, Clegg JC, Sidibe K. Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. *J Med Virol*. 1993;40(3):210-217. doi:10.1002/jmv.1890400308
- Fraser DW, Campbell CC, Monath TP, Goff PA, Gregg MB. Lassa Fever in the Eastern Province of Sierra Leone, 1970–1972: I. Epidemiologic Studies. *The American Journal of Tropical Medicine and Hygiene*. 1974;23(6):1131-1139. doi:10.4269/ajtmh.1974.23.1131
- 45. O'Hearn AE, Voorhees MA, Fetterer DP, et al. Serosurveillance of viral pathogens circulating in West Africa. *Virol J.* 2016;13:163. doi:10.1186/s12985-016-0621-4
- 46. Grant DS, Engel EJ, Yerkes NR, et al. Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study. *PLOS Neglected Tropical Diseases*. 2023;17(2):e0010938. doi:10.1371/journal.pntd.0010938
- 47. Sogoba N, Rosenke K, Adjemian J, et al. Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. *Emerg Infect Dis*. 2016;22(4):657-663. doi:10.3201/eid2204.151814
- Tobin. Lassa fever in Nigeria: Insights into seroprevalence and risk factors in rural Edo State: A pilot study. Accessed January 31, 2023. https://jmedtropics.org/article.asp?issn=2276-7096;year=2015;volume=17;issue=2;spage=51;epage=55;aulast=Tobin

- Merson L, Bourner J, Jalloh S, et al. Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design. *PLOS Neglected Tropical Diseases*. 2021;15(9):e0009788. doi:10.1371/journal.pntd.0009788
- 50. Nimo-Paintsil SC, Fichet-Calvet E, Borremans B, et al. Rodent-borne infections in rural Ghanaian farming communities. *PLOS ONE*. 2019;14(4):e0215224. doi:10.1371/journal.pone.0215224
- Fichet-Calvet E, Rogers DJ. Risk Maps of Lassa Fever in West Africa. *PLoS Negl Trop Dis*.
 2009;3(3):e388. doi:10.1371/journal.pntd.0000388
- Mylne AQN, Pigott DM, Longbottom J, et al. Mapping the zoonotic niche of Lassa fever in Africa. *Transactions of The Royal Society of Tropical Medicine and Hygiene*. 2015;109(8):483-492. doi:10.1093/trstmh/trv047
- 53. Bangura U. *Molecular Epidemiology of Lassa Virus in the Mano River Union Area, West Africa*. doctoralThesis. Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky; 2022. Accessed January 22, 2023. https://ediss.sub.uni-hamburg.de/handle/ediss/9660
- Demby AH, Inapogui A, Kargbo K, et al. Lassa Fever in Guinea: II. Distribution and Prevalence of Lassa Virus Infection in Small Mammals. *Vector-Borne and Zoonotic Diseases*. 2001;1(4):283-297. doi:10.1089/15303660160025912
- 55. Fichet-Calvet E, Becker-Ziaja B, Koivogui L, Günther S. Lassa Serology in Natural Populations of Rodents and Horizontal Transmission. *Vector-Borne and Zoonotic Diseases*. 2014;14(9):665-674. doi:10.1089/vbz.2013.1484
- 56. Olayemi A, Oyeyiola A, Obadare A, et al. Widespread arenavirus occurrence and seroprevalence in small mammals, Nigeria. *Parasit Vectors*. 2018;11:416. doi:10.1186/s13071-018-2991-5

- 57. Mariën J, Lo Iacono G, Rieger T, Magassouba N, Günther S, Fichet-Calvet E. Households as hotspots of Lassa fever? Assessing the spatial distribution of Lassa virus-infected rodents in rural villages of Guinea. *Emerg Microbes Infect*. 2020;9(1):1055-1064. doi:10.1080/22221751.2020.1766381
- Bangura U, Buanie J, Lamin J, et al. Lassa Virus Circulation in Small Mammal Populations in Bo District, Sierra Leone. *Biology (Basel)*. 2021;10(1):28. doi:10.3390/biology10010028
- 59. Agbonlahor DE, Erah A, Agba IM, et al. Prevalence of Lassa virus among rodents trapped in three South-South States of Nigeria. *J Vector Borne Dis*. 2017;54(2):146-150.
- Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study | PLOS Neglected Tropical Diseases. Accessed February 21, 2023. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010938#pntd.0010938.s001
- 61. Lerch A, ten Bosch QA, L'Azou Jackson M, et al. Projecting vaccine demand and impact for emerging zoonotic pathogens. *BMC Med*. 2022;20:202. doi:10.1186/s12916-022-02405-1
- Shaffer JG, Schieffelin JS, Gbakie M, et al. A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges. *PLOS ONE*. 2019;14(3):e0214284. doi:10.1371/journal.pone.0214284
- 63. Worldpop A Census Database. Accessed August 27, 2014. http://www.worldpop.org.uk/data/methods/
- 64. Redding DW, Gibb R, Dan-Nwafor CC, et al. Geographical drivers and climate-linked dynamics of Lassa fever in Nigeria. *Nat Commun*. 2021;12:5759. doi:10.1038/s41467-021-25910-y

- 65. Fichet-Calvet E, Lecompte E, Koivogui L, et al. Fluctuation of Abundance and Lassa Virus Prevalence in *Mastomys natalensis* in Guinea, West Africa. *Vector-Borne and Zoonotic Diseases*. 2007;7(2):119-128. doi:10.1089/vbz.2006.0520
- 66. Weiss DJ, Nelson A, Gibson HS, et al. A global map of travel time to cities to assess inequalities in accessibility in 2015. *Nature*. 2018;553(7688):333-336. doi:10.1038/nature25181
- 67. Barber RM, Fullman N, Sorensen RJD, et al. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. *The Lancet*. 2017;390(10091):231-266. doi:10.1016/S0140-6736(17)30818-8
- Olson DM, Dinerstein E, Wikramanayake ED, et al. Terrestrial Ecoregions of the World: A New Map of Life on Earth: A new global map of terrestrial ecoregions provides an innovative tool for conserving biodiversity. *BioScience*. 2001;51(11):933-938. doi:10.1641/0006-3568(2001)051[0933:TEOTWA]2.0.CO;2
- 69. ESA. Land Cover CCI Product User Guide Version 2. Published online 2017. Accessed June 26, 2023. http://maps.elie.ucl.ac.be/CCI/viewer/download/ESACCI-LC-Ph2-PUGv2_2.0.pdf
- 70. Hansen MC, Potapov PV, Moore R, et al. High-resolution global maps of 21st-century forest cover change. *Science*. 2013;342(6160):850-853. doi:10.1126/science.1244693
- 71. Tusting LS, Bisanzio D, Alabaster G, et al. Mapping changes in housing in sub-Saharan Africa from 2000 to 2015. *Nature*. 2019;568(7752):391-394. doi:10.1038/s41586-019-1050-5
- 72. Smits J, Steendijk R. The International Wealth Index (IWI). *Soc Indic Res*. 2015;122(1):65-85. doi:10.1007/s11205-014-0683-x

- Jagadesh S, Zhao C, Mulchandani R, Van Boeckel TP. Mapping Global Bushmeat Activities to Improve Zoonotic Spillover Surveillance by Using Geospatial Modeling. *Emerg Infect Dis*. 2023;29(4):742-750. doi:10.3201/eid2904.221022
- 74. Perkins TA, Huber JH, Tran QM, et al. Burden is in the eye of the beholder: Sensitivity of yellow fever disease burden estimates to modeling assumptions. *Sci Adv.* 2021;7(42):eabg5033.
 doi:10.1126/sciadv.abg5033
- 75. Ehichioya DU, Asogun DA, Ehimuan J, et al. Hospital-based surveillance for Lassa fever in Edo State, Nigeria, 2005–2008. *Tropical Medicine & International Health*. 2012;17(8):1001-1004. doi:10.1111/j.1365-3156.2012.03010.x
- Ugwu C, Olumade T, Nwakpakpa E, et al. Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria. *Sci Rep*. 2022;12(1):22330. doi:10.1038/s41598-022-26045-w
- 77. Monath TP, Mertens PE, Patton R, et al. A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. *The American Journal of Tropical Medicine and Hygiene*. 1973;22(6):773-779. doi:10.4269/ajtmh.1973.22.773
- 78. Fisher-Hoch SP, Tomori O, Nasidi A, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. *BMJ*. 1995;311(7009):857-859. doi:10.1136/bmj.311.7009.857
- 79. Dan-Nwafor CC, Ipadeola O, Smout E, et al. A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: description and lessons learned, 2018. *International Journal of Infectious Diseases*. Published online March 28, 2019. doi:10.1016/j.ijid.2019.03.030

- 80. Sogoba N, Feldmann H, Safronetz D. Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity. *Zoonoses and Public Health*. 2012;59(s2):43-47. doi:10.1111/j.1863-2378.2012.01469.x
- 81. Sogoba N, Rosenke K, Adjemian J, et al. Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. *Emerg Infect Dis*. 2016;22(4):657-663. doi:10.3201/eid2204.151814
- Lindgren F, Rue H, Lindström J. An explicit link between Gaussian fields and Gaussian Markov random fields: the stochastic partial differential equation approach. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*. 2011;73(4):423-498. doi:10.1111/j.1467-9868.2011.00777.x
- Bhatt S, Cameron E, Flaxman SR, Weiss DJ, Smith DL, Gething PW. Improved prediction accuracy for disease risk mapping using Gaussian process stacked generalization. *Journal of The Royal Society Interface*. 2017;14(134):20170520. doi:10.1098/rsif.2017.0520
- 84. Barua S, Dénes A, Ibrahim MA. A seasonal model to assess intervention strategies for preventing periodic recurrence of Lassa fever. *Heliyon*. 2021;7(8):e07760. doi:10.1016/j.heliyon.2021.e07760
- 85. Leski TA, Stockelman MG, Moses LM, et al. Sequence Variability and Geographic Distribution of Lassa Virus, Sierra Leone. *Emerg Infect Dis*. 2015;21(4):609-618. doi:10.3201/eid2104.141469
- Happi AN, Olumade TJ, Ogunsanya OA, et al. Increased Prevalence of Lassa Fever Virus-Positive Rodents and Diversity of Infected Species Found during Human Lassa Fever Epidemics in Nigeria. Anderson MZ, ed. *Microbiol Spectr*. 2022;10(4):e00366-22. doi:10.1128/spectrum.00366-22
- Klitting R, Kafetzopoulou LE, Thiery W, et al. Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades. *Nat Commun*. 2022;13:5596. doi:10.1038/s41467-022-33112-3

- Omilabu SA, Badaru SO, Okokhere P, et al. Lassa Fever, Nigeria, 2003 and 2004. *Emerg Infect Dis*.
 2005;11(10):1642-1644. doi:10.3201/eid1110.041343
- Dan-Nwafor CC, Ipadeola O, Smout E, et al. A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: Description and lessons learned, 2018. *International Journal of Infectious Diseases*. 2019;83:88-94. doi:10.1016/j.ijid.2019.03.030
- Shaibu JO, Salu OB, Amoo OS, et al. Immunological screening of Lassa Virus among Health workers and Contacts of patients of Lassa fever in Ondo State. *Immunobiology*. 2021;226(3):152076. doi:10.1016/j.imbio.2021.152076
- 91. Fick SE, Hijmans RJ. WorldClim 2: new 1-km spatial resolution climate surfaces for global land areas. International Journal of Climatology. 2017;37(12):4302-4315. doi:10.1002/joc.5086
- 92. Didan K. Mod13a3 modis/terra vegetation indices monthly I3 global 1km sin grid v006. NASA EOSDIS Land Processes DAAC. 2015;10.
- 93. Abrams M, Crippen R, Fujisada H. ASTER Global Digital Elevation Model (GDEM) and ASTER Global Water Body Dataset (ASTWBD). *Remote Sensing*. 2020;12(7):1156. doi:10.3390/rs12071156
- 94. Schneider A, Friedl MA, Potere D. A new map of global urban extent from MODIS satellite data. *Environ Res Lett*. 2009;4(4):044003. doi:10.1088/1748-9326/4/4/044003
- 95. Nachtergaele F, Petri M. Mapping Land Use Systems at Global and Regional Scales for Land Degradation Assessment Analysis Freddy Nachtergaele. Land Degradation Assessment in Drylands; 2008. Accessed March 21, 2023. https://www.researchgate.net/profile/F-Nachtergaele/publication/265754296_Mapping_Land_Use_Systems_at_global_and_regional_scales _for_Land_Degradation_Assessment_Analysis_Version_10/links/5437eebb0cf2027cbb205c28/Map

ping-Land-Use-Systems-at-global-and-regional-scales-for-Land-Degradation-Assessment-Analysis-

Version-10.pdf

96. Weiss DJ, Lucas TCD, Nguyen M, et al. Mapping the global prevalence, incidence, and mortality of

Plasmodium falciparum, 2000–17: a spatial and temporal modelling study. *The Lancet*.

2019;394(10195):322-331. doi:10.1016/S0140-6736(19)31097-9